







































































































































































































































risk	 of	 recurrence.	 Cell	 stress	 following	 hyperglycaemia	 or	 hypoxia	 reduces	 fumarate	
hydratase	(FH)	activity	promoting	increased	intracellular	fumarate.	Fumarate	irreversibly	
modifies	 cysteine	 residues	 by	 succination	 to	 form	 2-succino-cysteine	 (2-SC)	which	 can	
inactivate	proteins.		













cetuximab	 treatment	 inhibited	 STAT1	 activation,	 oxaliplatin-induced	 DUOX2	
upregulation,	and	ROS	generation.	This	may	explain	why	CRC	patients	on	oxaliplatin	alone	
have	 a	 better	 prognosis	 than	 those	 treated	 with	 a	 combination	 of	 oxaliplatin	 and	
cetuximab.	
This	 work	 has	 increased	 our	 understanding	 of	 CRC	 and	 aspects	 linked	 indirectly	 to	







Valeria	 Santoro,	 Ruochen	 Jia,	 Hannah	 Thompson,	 Anke	 Nijhuis,	 Rosemary	 Jeffery,	
Konstantinos	 Kiakos,	 Andrew	 R.	 Silver,	 John	 A.	 Hartley,	 Daniel	 Hochhauser.	 Role	 of	




Hannah	 Thompson,	 Julie	 Adam,	 Kathryn	 Lynes,	 Amy	 Lewis,	 Hayley	 Davies,	 Rosemary	






Anke	 Nijhuis,	Hannah	 Thompson,	 Julia	 Adam,	 Alexandra	 Parker,	 Luke	 Gammon,	 Amy	
Lewis,	 Jake	 Bundy,	 Tomoyoshi	 Soga	 T,	 Aleshi	 Jalaly,	 David	 Propper,	 Rosemary	 Jeffery,	
Nirosha	Suraweera,	 Sarah	McDonald,	Mohammed	Thaha,	Roger	Feakins,	Robert	 Lowe,	
Cleo	Bishop,	Andrew	Silver.	Remodelling	of	microRNAs	 in	 colorectal	 cancer	by	hypoxia	









































mention	 to	 other	 members	 of	 the	 Talent	 Factory	 (science	 communication	 and	

























































































6.1	 Effect	 of	 oxaliplatin	 and	 cetuximab	 treatment	 of	 DLD1	
xenografts	on	DUOX2	and	DUOXA2	mRNA.		
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6.2	 Effect	 of	 oxaliplatin	 and	 cetuximab	 treatment	 of	 DLD1	
xenografts	on	DUOX2	protein	expression.	
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A.5.1	 The	 normalised	 RT-PCR	 data	 for	GLUT1,	GLUT4,	GADPH	 and	
GPX1	expressed	as	 fold	change	 from	cells	 cultured	 in	25mM	
glucose	at	20.9%	O2.	
306	































































































































A.3.4	 Summary	 of	 Bonferroni	 post	 hoc	 test	 of	 2-SC	 scores	 for	matched	
normal	and	adenoma	tissue.	
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A.5.8	 Summary	 of	 Bonferroni	 post	 hoc	 test	 values	 for	 fumarate	
concentration.	
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A.5.15	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 DLD1	 cells	
cultured	in	5mM	glucose.	
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A.5.16	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 DLD1	 cells	
cultured	in	0mM	glucose.	
299	
A.5.17	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 HT55	 cells	
cultured	in	25mM	glucose.	
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A.5.18	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 HT55	 cells	
cultured	in	5mM	glucose.	
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A.5.19	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 HT55	 cells	
cultured	in	0mM	glucose.	
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A.5.20	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 SW837	 cells	
cultured	in	25mM	glucose.	
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A.5.21	 Summary	 of	 normalised	 values	 for	 RT-PCR	 data	 for	 SW837	 cells	
cultured	in	5mM	glucose.	
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cause	of	 death2.	 In	 total,	 CRC	 accounts	 for	 9%	of	 cancer-related	deaths	worldwide,	 of	
which	90%	are	from	metastasis3.	 In	developed	countries,	almost	half	of	the	population	
will	 develop	 at	 least	 one	 benign	 intestinal	 tumour	 (adenoma)	 during	 their	 lifetime2.	
Although	CRC	survival	has	increased	year	on	year	since	the	1960's4,	survival	rates	are	still	
poor	with	no	significant	difference	 in	mortality	between	male	and	 female	cases	 (Table	
1.1).		
The	most	obvious	symptoms	of	CRC	are	blood	in	the	faeces,	a	change	in	bowel	habit	and	

























Years	post-diagnosis	 All	adults	 Men	 Women	
0	 100	 100	 100	
1	 75.7	 77.4	 73.9	
2	 67.9	 69.5	 66.3	
3	 63.2	 64.5	 61.9	
4	 60.4	 61.2	 59.5	
5	 58.7	 59.2	 58.2	
6	 57.7	 57.5	 58.0	
7	 57.1	 57.2	 57.1	
8	 56.8	 56.6	 57.0	
9	 56.6	 56.3	 57.1	

















(Figure	 1.2).	 Sequential	 mutations	 in	 adenomatous	 polyposis	 coli	 (APC),	 Kirsten	 rat	
sarcoma	(KRAS)	and	smooth	mothers	against	decapentaplegic	homolog	(SMAD)	2/4	lead	
to	 transitions	 through	 early,	 intermediate	 and	 late	 adenoma,	 respectively.	 A	 loss	 of	
function	mutation	in	tumour	protein	53	(TP53)	transforms	the	adenoma	into	a	carcinoma.	
Subsequent	 genetic	 mutations	 occur	 which	 promote	 carcinogenesis	 and	 metastasis	
(Figure	1.2).	
Large	scale	sequencing	of	CRC	tissue	has	demonstrated	the	presence	of	tens	of	thousands	












repeats	 (20AARs)	 that	 are	 critical	 functional	 domains	 for	 binding	 of	 β-catenin	 (Figure	
1.3.C)19.	Proximal	CRC	tumours	show	enrichment	for	mutations	which	retain	2-3	20AARs	
whereas	 distal	 cancers	 predominantly	 have	 APC	 mutations	 which	 retain	 0-1	 20AARs	
indicating	selection	of	distinct	Wnt/β-catenin	signalling	which	 is	 favourable	 for	 tumour	
progression	dependent	on	location,	as	described	by	the	“just-right”	theory19,20.	When	APC	
is	 mutated,	 β-catenin	 is	 able	 to	 translocate	 to	 the	 nucleus	 where	 it	 binds	 to	 other	
	 29	
transcription	factors	to	form	a	complex,	which	 leads	to	the	transcription	of	Wnt	target	








leads	 to	 activation	 of	 the	 Wnt	 pathway,	 which	 leads	 to	 an	 early	 adenoma.	 Next,	 a	
mutation	in	KRAS	leads	to	activation	of	the	EGFR	pathway,	promoting	transformation	to	
an	 intermediate	 adenoma.	 Then,	 mutations	 in	 Smad	 2/4	 lead	 to	 TGFß	 pathway	
inactivation	and	 transformation	 to	a	 late	adenoma.	A	 loss	of	 function	mutation	 in	p53	
then	 leads	 to	 carcinoma	 formation,	with	additional	 genetic	mutations	occurring	which	
promote	metastasis23.	APC,	adenomatous	polyposis	coli;	KRAS,	Kirsten	rat	sarcoma;	EGFR,	


















co-ordinator	 of	 cell–cell	 adhesion	 and	 gene	 transcription	 (C)	APC	mutations	 cluster	 in	
codon	1282-1581	to	produce	truncated	proteins	which	retain	1-3	of	the	20AARs	that	are	
critical	 functional	domains	 for	binding	of	β-catenin,	adapted	 from	Pollard	et	al	 200915.	



















differentiation.	 Recent	 studies	 have	 identified	 three	 genes	 encoded	 on	 the	 18q	
chromosome	which	are	lost	in	79%	of	CRC	tumours:	phosphatidylinositol	glycan	anchor	
biosynthesis	 class	 N	 (PIGN);	 mex-3	 homolog	 C	 (MEX3C);	 and	 zinc	 finger	 protein	 516	
(ZNF516)33.		













therefore	 tumour	 promotion41.	 EGFR,	 epidermal	 growth	 factor	 receptor;	 PLC,	
phospholipase	C;	JAK,	janus	kinase;	SRC,	cellular	Src	kinase;	PI3K,	phosphatidylinositol	3-
kinase;	PKC,	protein	kinase	C;	STAT,	signal	transducer	and	activator	of	transcription;	PTEN,	










CIN	 develops	 in	 the	 large	 majority	 (~60%)	 of	 CRC	 cases	 and	 is	 characterised	 by	 an	
accelerated	 rate	 of	 allelic	 gains	 or	 losses	 and	 gross	 chromosomal	 abnormalities.	 CIN	
tumours	therefore	have	an	 imbalance	 in	chromosome	number	(aneuploidy)	and	a	high	
frequency	 of	 loss	 of	 heterozygosity	 (LOH)	 where	 an	 entire	 gene	 and	 the	 surrounding	
chromosome	region	are	lost.	Frequently	mutated	genes	in	CIN	tumours	are	APC,	TP53	and	
KRAS	33.	CIN	tumours	have	recently	been	divided	into	two	groups	depending	on	telomere	








genes:	 MutL	 homolog	 1	 (MLH1),	 MutS	 homolog	 (MSH)	 2,	MSH3,	MSH6,	 post-meiotic	














Georgiades	 and	 colleagues48.	 MACS	 tumours	 are	 more	 likely	 to	 develop	 in	 younger	
patients49	and	are	localised	to	the	distal	colon	as	well	as	being	poorly	differentiated	and	








































develop	 many	 precancerous	 colonic	 polyps	 in	 their	 mid-teens.	 FAP	 patients	 carry	 a	
mutation	 in	one	APC	allele63,64.	The	 location	of	 the	 ‘second	hit’	mutation	which	causes	
progression	 to	 FAP	 in	 linked	 to	 the	 location	 of	 the	 initial	mutation.	 FAP	 patients	with	




































































recently	 described	 polymerase	 proofreading-associated	 polyposis.	 Hamartoma	








and	 survival	 of	 malignant	 cells76,77.	 	 One	 consequence	 of	 inflammation	 in	 the	 gut	 is	
increased	 risk	of	 field	 cancerisation	where	 the	normal	 cell	 population	 is	 replaced	by	 a	
histologically	 non-dysplastic	 but	 pro-tumourigenic	 cell	 population78,79.	 IBD	 can	 also	
directly	 result	 in	dysplasia,	an	abnormal	collection	of	cells	 in	 the	 lining	of	 the	colon	or	


























of	 bacteria	 identified	 to	 have	 a	 role	 in	 CRC	 progression	 including	 Streptococcus	 bovis,	
Helicobacter	 pylori,	 Bacteroides	 fragilis,	 Enterococcus	 faecalis,	 Clostridium	 septicum,	
Fusobacterium	spp.	and	Escherichia	coli88–91.	Recent	evidence	suggests	 that	altered	gut	
microbiota	 is	 present	 in	 patients	 with	 adenomas92	 suggesting	 that	 an	 imbalance	 in	
intestinal	microbiota	promotes	 the	early	 stages	of	CRC.	More	 research	 is	necessary	 to	
determine	 correlations	 between	 changes	 in	 intestinal	 environment	 and	 microbiota	
homeostasis.	
1.4.7. Smoking	
Long-term	 smokers	 are	 2.14	 times	more	 likely	 than	 non-smokers	 to	 develop	 CRC93.	 In	
total,	 smoking	 has	 been	 attributed	 as	 the	 cause	 of	 12%	 of	 all	 CRC94	 and	 is	 associated	
dramatically	with	poorer	prognosis	after	diagnosis:	meta-analyses	yielded	random-effects	
hazard	ratio	estimates	(95%	confidence	intervals	(CI))	for	all-cause	mortality	of	1.26	(1.15–









1.13-1.28)	 and	 1.52	 (95%	CI	 1.27-1.81)	 for	 heavy	 alcohol	 intake.	 The	RR	 for	moderate	
alcohol	intake,	compared	with	non-/occasional	alcohol	intake,	was	stronger	for	men	(RR	
=	1.24,	95%	CI	1.13-1.37)	than	for	women	(RR	=	1.08,	95%	CI	1.03-1.13).	The	mechanism	

















high	 and	 low	 levels	 of	 physical	 activity.	 Biological	 mechanisms	 of	 CRC	 prevention	 by	
















Methods	of	CRC	diagnosis	 vary	between	 countries.	 In	 the	UK,	 there	 is	 a	bowel	 cancer	
screening	service	which	uses	two	methods	used	to	detect	CRC	in	 its	earliest	stage.	The	
first	 is	 a	 one-off	 bowel	 scope	 screening	 for	 55	 year	 olds112.	 Polyps	 in	 the	 bowel	 are	
indicative	of	CRC	risk:	adenomatous	polyps	are	a	pre-cancerous	polyp	with	the	potential	
to	transform	into	cancer	whereas	hyperplastic	and	inflammatory	polyps	are	not	currently	
considered	pre-cancerous113.	 In	 the	United	States	 (US),	patients	are	screened	from	the	
earlier	age	of	50.	Screening	in	the	US	has	been	credited	as	the	main	reason	for	the	6%	
decline	in	cases,	between	2005	and	2014114.	The	second	diagnostic	test	available	in	the	





sample	 with	 sources	 other	 than	 human	 haemoglobin,	 like	 diet.	 Unfortunately,	 this	
technique	is	more	expensive	so	is	not	widely	used117.		
Once	a	 lesion	 is	suspected,	 the	next	step	 is	a	 flexible	sigmoidoscopy	or	a	colonoscopy.	
Both	 permit	 the	 removal	 of	 adenomas	 at	 the	 same	 time,	 reducing	 cancer	 incidence.	
Biopsy	samples	removed	during	the	procedure	are	sent	for	histopathological	assessment	
and	 genetic	 testing	 can	 be	 undertaken	 to	 provide	 further	 information.	 However,	
endoscopic	procedures	require	bowel	preparation,	carry	a	risk	of	complications,	such	as	
























emission	 tomography	 (PET)	 scans	 can	 identify	 small	 metastases	 well120.	 Imaging	












Figure	 1.5.	 TNM	 staging	 of	 CRC.	 T	 represents	 the	 primary	 tumour	 and	 the	 level	 of	
penetration	 into	 the	 lining	 of	 the	 bowel	 and	 nearby	 tissues	 in	 more	 severe	 cases;	 N	
represents	the	spread	of	the	cancer	cells	to	regional	lymph	nodes;	and	M	represents	the	

























































Surgery,	 chemotherapy	 and	 radiotherapy	 all	 have	 key	 roles	 in	 the	 treatment	 of	 CRC	
dependent	on	stage.	Surgery	is	the	main	treatment	for	all	stages	of	rectal	cancer	and	the	
early	 stages	 (T1-2)	 of	 colon	 cancer,	 when	 the	 cancer	 remains	 localised,	 are	 often	
considered	curative.	During	surgery,	nearby	 lymph	nodes	are	also	 removed	 to	prevent	
recurrence.		
Chemotherapy	 remains	 the	 standard	 of	 care	 for	 the	 50%	 of	 patients	 that	 develop	





(FOLFIRI).	 Newer	 targeted	 agents	 include	 antibodies	 against	 tumour	 antigens	 that	 are	
used	 depending	 on	 the	 patient’s	 mutation	 profile125–128.	 Patients	 with	 RAS	 mutant	
tumours	(mutation	in	KRAS,	usually	codon	12	and	13,	or	NRAS	exon	2,	3	and	4)	are	treated	
with	Bevacizumab	(anti-vascular	endothelial	growth	factor	(VEGF)-A	antibody)	whereas	




to	 therapy	 are	 needed	 for	 more	 reliable	 stratification	 of	 patients	 for	 proper	 clinical	
management.	 However,	 second-line	 therapeutics	 are	 available:	 Regorafenib	 a	 non-




Recently,	 the	new	Eloxatin	Peri-Operative	Chemotherapy	 (EPOC)	 study	of	 combination	





1.8)	 generated	 by	 dual	 oxidase	 (DUOX)-2	 as	 a	 result	 of	 cetuximab	 treatment	 reduced	
oxaliplatin	activity133	(detailed	in	Chapter	6).	DUOX2	is	a	175kDa	enzyme	which	is	part	of	
the	 nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH)	 oxidase	 (NOX)	 family.	 The	




defence	 system	 of	 the	 airway	 epithelium	 and	 the	 human	 gastrointestinal	 tract136–139.	
DUOX	proteins	are	found	in	the	apical	membrane	and	in	the	enterocytes	of	the	human	
colon140.	It	is	known	that	hypoxia	increases	the	expression	of	DUOX2	in	the	gut139.		High	
levels	 of	 DUOX2	 have	 been	 observed	 in	 the	 colonic	 epithelium	of	 IBD	 patients	 and	 in	
colonic	and	pancreatic	cancers141.	Recently,	DUOX2	has	been	shown	to	be	regulated	by	a	
signal	 transducer	 and	 activator	 of	 transcription	 (STAT)-dependent	 janus	 kinase	 (JAK)	
independent	pathway142.		
Radiation	therapy	is	also	a	treatment	arm	for	rectal	cancer.	Radiation	works	by	damaging	
the	 cell’s	 DNA	 leading	 to	 cell	 death.	 Radiation	 is	 often	 given	 alongside	 chemotherapy	
before	and/or	after	surgery	to	remove	any	remaining	cancerous	cells.	This	type	of	therapy	
is	also	used	to	treat	metastases,	mainly	those	that	have	spread	to	the	bones143.		
There	 are	 a	 variety	 of	 clinical	 trials	 underway	 and	 others	 completed	 recently	 for	 CRC	
treatment.	For	primary	CRC,	 the	 focus	 is	on	 improving	screening	accuracy	and	surgical	
techniques.	For	metastatic	CRC,	there	are	a	variety	of	targeted	therapies,	which	have	been	














Formation	of	 vessels	 in	 tumours	 is	not	 carefully	 co-ordinated	 like	normal	physiological	
angiogenesis,	 leading	 to	 vascular	 leakiness,	 chaotic	 architecture,	 non-laminar	 blood	
flow147	and	dynamic	fluctuations	in	blood	flow	called	‘cycling	hypoxia’153.	Hypoxic	areas	in	
tumours	are	formed	as	a	consequence	of	the	metabolic	demands	of	proliferating	cancer	
cells	and/or	 functionally	 limited	vasculature154.	There	 is	often	heterogeneity	 in	 tumour	
oxygenation	 with	 hypoxic	 and	 necrotic	 areas	 characteristically	 observed	 towards	 the	
centre	of	 the	 tumour.	 Experimental	 evidence	demonstrates	 steep	 gradients	 of	 oxygen	
partial	 pressure	 that	 are	 close	 to	 zero	when	 cells	 are	 distant	 from	 vessels155,	 with	 an	











1.6).	 This	 leads	 to	 transcriptional	 activation	 of	 more	 than	 30	 genes	 which	 promotes	
	 50	
aberrant	 cell	 survival	 alongside	 a	 switch	 in	 cellular	metabolism	 to	 anaerobic	 glycolysis	
enabling	disease	progression160.	These	genes	include	glucose	transporter	(GLUT)-1	which	
facilitates	cellular	glucose	uptake;	hexokinase	(HK)-2	and	lactate	dehydrogenase	(LDH)-A	




cancers	 including	 bladder,	 breast,	 lung,	 ovary,	 pancreas,	 stomach	 and	 colon162.	 High	





DNA	damage	 and	 subsequent	 genomic	 instability	 and	 result	 from	 increased	metabolic	
activity,	mitochondrial	 dysfunction	and	oncogene	activity.	 Cancer	 cells	 also	express	 an	
increased	level	of	antioxidant	proteins	to	neutralise	ROS,	suggesting	a	delicate	balance	of	
ROS	is	necessary	for	cancer	cell	function164.		















regulated	 by	 VHL	 leading	 to	 continuous	 degradation	 by	 the	 ubiquitin-proteasome	
pathway.	(B)	In	hypoxic	conditions,	VHL	is	downregulated.	HIF-1α	is	stabilised	and	free	to	
dimerise	with	HIF-1β	which	then	binds	as	a	complex	to	HRE	within	the	genome,	promoting	














Physiologically,	 normal	 cells	 have	 a	 low	 rate	 of	 glycolysis	with	most	 energy	 efficiently	
generated	 by	 oxidative	 phosphorylation	 in	 the	 mitochondria.	 In	 general	 cancer	 cells	
mainly	use	glycolysis	to	generate	adenosine	triphosphate	(ATP).		






source	 of	 energy	 for	 cancer	 cells169	 (Figure	 1.8).	 During	 the	 TCA	 cycle	 nicotinamide	
adenine	dinucleotide	(NADH)	is	produced	which	then	serves	as	an	electron	donor	in	the	
electron	 transport	 chain	 (ETC),	 where	 30-36	molecules	 of	 ATP	 are	 produced	 for	 each	
glucose	molecule	via	oxidative	phosphorylation	(OXPHOS)	in	the	inter-membrane	space	
of	mitochondria168	(Figure	1.9).	Oxygen	is	used	as	an	electron	acceptor	for	OXPHOS.	In	the	






rates	 of	 200	 times	 that	 of	 a	 normal	 cell173.	 	 Cancer	 cells	 in	 general	 are	metabolically	
adapted	to	grow	and	proliferative	rapidly	under	conditions	of	low	pH	and	oxygen	tension	
with	 limited	 nutrients174	 where	 non-transformed	 cells	 would	 struggle	 to	 grow175.	 An	
important	study	by	Sonveaux	et	al.	 in	2008176	showed	that	normoxic	tumour	areas	can	
oxidise	 lactate	as	a	significant	carbon	source,	sparing	glucose	and	allowing	 it	to	diffuse	




















Figure	 1.8.	 The	 tri-carboxylic	 acid	 cycle.	 Acetyl-CoA	 enters	 the	 TCA	 cycle	 in	 the	
mitochondria	where	it	is	broken	down	via	nine	further	enzymatic	steps	to	oxaloacetate168.	
Glutamine	 can	 also	 enter	 the	 TCA	 cycle.	 TCA,	 tricarboxylic	 acid	 cycle;	 PHD,	 prolyl	














generated	 by	 the	 TCA	 cycle	 are	 transferred	 through	 a	 chain	 of	 protein	 complexes	
embedded	in	the	inner	mitochondrial	membrane177.	The	oxidation	steps	lead	to	protons	







The	exact	 reason	 for	 the	 switch	 in	glucose	metabolism	pathways	 in	 cancer	 cells	 is	not	
known,	although	there	are	a	number	of	theories:	1)	an	inherent	feature	of	the	malignant	
phenotype,	 called	 the	Warburg	 effect178,179;	 2)	 as	 a	 consequence	 of	 a	 hypoxic	 tumour	
microenvironment167,	or	3)	the	existence	of	a	pseudo-hypoxic	tumour	metabolic	profile173.	
	
Otto	Warburg	was	 the	scientist	who	discovered	 the	 ‘oxidative	glycolytic’	phenotype	of	
cancer	cells.	In	these	cells,	glycolysis	is	uncoupled	from	the	mitochondrial	TCA	cycle	and	
OXPHOS,	and	is	consequently	characterised	by	excess	production	of	lactate	leading	to	an	








monocarboxylate	 transporter	 (MCT)-1	 and	 HIF-1a	 which	 indicates	 increased	 glycolytic	
metabolism	and	lactate	production182.	In	CRC,	LDHA5,	which	converts	pyruvate	to	lactate,	








tumour	 suppressors	 are	 to	 reprogram	 cellular	 metabolism	 (reviewed	 in188).	 Carbon	
labelling	metabolic	 studies	have	 identified	 that	 in	solid	 tumours,	where	glucose	supply	
can	 be	 low189,	 glutaminolysis,	 the	 TCA	 cycle,	 the	 pentose	 phosphate	 pathway	 and	
















all	 which	 have	 been	 shown	 to	 be	 relevant	 in	 CRC	 tumorigenesis	 and	 linked	 to	 poor	
prognosis182,195	 (Figure	 1.10).	 HIF-1	 also	 promotes	 the	 expression	 of	 pyruvate	
dehydrogenase	kinase	(PDK)-1	expression162	which	acts	to	block	conversion	of	pyruvate	
to	 acetyl-CoA,	 effectively	 blocking	 the	 TCA	 cycle	 and	 OXPHOS,	 forcing	 the	 cell	 to	 use	
glycolysis	for	ATP	generation.	Upregulation	of	PDK1	also	protects	cells	from	ROS	damage.	
There	 is	evidence	 to	 suggest	 that	HIF-1	down	 regulates	mitochondrial	biogenesis162	by	







heterodimer197.	 MAX	 is	 itself	 regulated	 by	 binding	 of	 MAX	 dimerisation	 protein	
(MXD1/MAD)	 and	 MAX	 interactor	 1	 (MX11/MAD2)198.	 MX11	 binding	 to	 MAX	 inhibits	
binding	 of	 MYC:MAX	 to	 E-boxes.	 HIF-1α	 can	 also	 interfere	 with	 the	 MYC:MAX	
heterodimer;	through	upregulation	of	MX11,	 increasing	competition	for	MAX199	and	by	
direct	 binding	 of	 MAX	 to	 displace	 MYC.	 Conversely,	 HIF-2α	 binds	 and	 stabilises	 the	
MYC:MAX	heterodimer	to	promote	MYC	associated	transcriptional	changes200.	HIFα	can	
	 58	
be	 outcompeted	 in	 tumours	 with	 high	 expression	 levels	 of	 MYC201,	 therefore,	 HIF-2α	
interaction	 with	 the	 MYC:MAX	 heterodimer	 is	 more	 likely	 to	 influence	 the	 hypoxia-
induced	metabolic	transformation	 in	non-MYC-amplified	tumours.	There	are	no	known	
mutations	 of	MYC	 in	 CRC.	 However,	MYC	 is	 frequently	 amplified	 in	 CRC;	 Soga	 et	 al.	
recently	implicated	amplification	of	MYC,	which	is	commonly	seen	in	CRC,		leads	a	change	
in	 expression	 of	 121	 metabolic	 genes	 and	 39	 transporter	 genes	 in	 CRC	 promoting	
metabolic	reprogramming202.		
The	relationship	between	TP53	and	hypoxia	is	controversial;	hypoxia	has	been	shown	to	
induce	TP53	 stability	 in	 some	conditions,	but	not	 in	others203,204.	 It	 appears	 that	 lower	
oxygen	 tensions	 elicit	 strong	 stabilisation	 of	 TP53,	 through	 DNA	 damage-response	
mechanisms205.	Stabilisation	of	TP53	increases	the	entry	of	glycolytic	intermediates	into	
the	pentose	phosphate	and	folate	pathway	by	modulation	of	key	enzymes206,207.	 In	this	




Pseudo-hypoxia	 is	 the	 activation	 of	 the	 hypoxia	 response	 pathway	 under	 non-hypoxic	
conditions	which	 is	 commonly	 seen	 in	 cancers209,	 although	 this	has	not	been	 reported	
specifically	 in	 CRC	 to	 date.	 Defects	 in	 some	 TCA	 cycle	 enzymes	 lead	 to	 decreased	












there	are;	(A)	Changes	 in	pathways	as	a	result	of	changes	 in	O2	tension,	(B)	changes	 in	
specific	 proteins	 as	 a	 result	 of	 changes	 in	 O2	 tension	 and	 (C)	 changes	 in	 transcript	
expression152.	ROS,	reactive	oxygen	species;	PHD,	prolyl	hydroxylase	domain-containing	
protein;	OXPHOS,	oxidative	phosphorylation;	HIF,	hypoxia	inducible	factor;	LDHA,	lactose	













largely	 been	 conserved212	 and	 most	 cancer	 pathways	 operate	 in	 both	 species213.	 The	
genomes	 of	 inbred	 laboratory	 mice	 are	 well	 characterised;	 they	 are	 considered	
homozygous	at	every	locus	and	are	housed	in	a	controlled	environment.	However,	there	
are	 some	 drawbacks.	 Inbred	 laboratory	 mice	 lack	 the	 genetic	 heterogeneity	 which	 is	
present	 in	 the	human	population;	human	tumours	are	more	heterogeneous	than	their	
mouse	 counterparts214,215.	 The	 lack	 of	 complexity	 poses	 problems	 when	 trying	 to	
recapitulate	 faithfully	 the	 human	 disease	 for	 pre-clinical	 studies	 particularly	 as	 the	
heterogeneity	 of	 human	 tumours	 results	 in	 greater	 potential	 for	 the	 development	 of	
resistance	 to	 therapy	 and	 for	 recurrence	 after	 surgical	 resection216.	 	 Humans	 also	
experience	a	more	varied	diet	and	have	a	different	microbiome	compared	to	the	mouse,	
which	 exposes	 human	 intestinal	 epithelial	 cells	 to	more	 exogenous	 genotoxins217.	 The	
difference	 in	 life	 span	 between	 man	 and	 mouse	 is	 also	 a	 problem.	 In	 man,	 the	
development	of	CRC	is	over	a	much	longer	period	compared	to	mouse,	and	mice	often	
become	anaemic	 as	 a	 consequence	of	 polyposis	 and	have	 to	be	 sacrificed	before	CRC	
develops218.	There	are	also	crucial	differences	in	telomere	maintenance	and	function219.	
Telomeres	 shorten	 with	 each	 mitotic	 cell	 division	 but	 are	 elongated	 by	 telomerase.	
Although	telomere	sequence	is	identical	in	mice	and	humans,	heterozygous	telomerase	
mutations	 in	humans	is	sufficient	to	result	 in	cancer	development,	but	 laboratory	mice	














ApcMin/+	mouse	 is	 widely	 used	 in	 research	 today.	 More	 sophisticated	 knock-in	 and/or	
knock-out	mouse	models	enable	further	functional	study	of	genetic	mutations	involved	in	
CRC.	The	 cancer	genome	atlas	 (TCGA)	has	 identified	many	genes	which	are	 frequently	
mutated	in	many	different	types	of	malignancy,	often	referred	to	as	pan-cancer	genes,	
this	 suggests	 a	 role	 for	 these	 genes	 in	 the	 progression	 of	 cancer224.	 It	 is	 possible	 to	
introduce	genetic	mutations	 into	specific	 tissues	 in	mice;	 these	models	can	be	used	to	
determine	 if	mutations	are	passenger	or	driver	mutations225.	For	example,	 the	Apc1322T	
mouse	has	a	mutation	in	APC	specifically	in	the	bowel	(Figure	1.3).	The	use	of	Apc	mutant	









mutant	 mice	 were	 developed,	 but	 unlike	 their	 human	 counterparts	 the	 mice	 never	
develop	metastases.	 To	 try	 and	 recapitulate	metastases,	Apc	 mutant	mice	 have	 been	
crossed	to	mice	with	gene	mutations	found	in	the	later	stage	of	disease	including	TP53,	















the	 development	 of	 CRC.	 For	 example,	 in	 CRC	 T-cell	 infiltrate	 is	 predictive	 of	 patient	
survival228	 and	 mice	 with	 deletion	 of	 SMAD4	 in	 T-cells	 excessively	 secrete	 pro-
inflammatory	cytokines	which	leads	to	the	development	of	gastrointestinal	tumours229.	
Secondly,	 few	cell	 lines	 lead	 to	 reliable	primary	 tumour	growth	and	even	 less	produce	
naturally	metastatic	CRC230.		Success	rates	are	highest	when	using	HCT116	and	HT29	cell	
lines	but	 it	 is	 not	understood	why216.	 Thirdly,	 orthotopic	 and	 subcutaneous	 xenografts	
show	differing	sensitivities	to	chemotherapeutic	agents231,232	and	site	of	injection,	mouse	




The	 environment	 of	 a	 subcutaneous	 xenograft	 is	 very	 different	 from	 that	 of	
autochthonous	 tumours	 and	 the	 extent	 to	 which	 mismatch	 of	 tumour	 (human)	 and	
stromal	 (mouse)	 influences	 the	 growth	 of	 the	 tumour	 is	 uncertain216.	 Orthotopic	
xenografts	 introduce	 cells	 to	 a	 more	 natural	 environment,	 such	 as	 the	 serosa	 of	 the	
intestine,	and	these	models	do	result	in	more	reliable	liver	metastasis231.	Patient-derived	
orthotopic	 xenografts	 are	 another	 option.	 They	 avoid	 natural	 selection	 of	 dominant	














Diabetes	mellitus	 (DM)	 is	 a	 chronic	 disease	 caused	by	 dysregulated	 insulin	 production	
from	pancreatic	β-cells	leading	to	elevated	blood	glucose	(hyperglycaemia).	Insulin	works	
to	 promote	 the	 uptake	 of	 glucose	 into	 cells.	 Normal	 homeostatic	 control	maintains	 a	
blood	 glucose	 concentration	 of	 between	 4	 to	 8mM,	 with	 tissue	 levels	 of	 glucose	









twice	 the	 risk	of	a	non-diabetic	person	due	 to	 its	association	with	a	wide	 range	of	 co-
morbidities	 and	 complications	 including	 Alzheimer’s239,	 Parkinson’s	 disease240,	
cardiovascular	disease241,	cancer242,	depression243,	kidney	problems244,	liver	failure245	and	
retinopathy246.	













T1D	 is	 also	 known	as	 insulin-dependent	diabetes	mellitus	 (IDMM)	or	 juvenile	diabetes	
where	 the	 pancreatic	 β-cells	 are	 destroyed	 by	 an	 autoimmune	 response251.	 T1D	often	
develops	suddenly	in	childhood	with	symptoms	of	fatigue	and	excessive	urine	excretion.	
Risk	factors	are	viral	infections	like	German	measles,	living	in	a	northern	climate,	genetics	







Sophisticated	 laboratory	 tests	 are	 required	 to	 distinguish	 between	 T1D	 and	 T2D	 it	 is	
difficult	to	find	accurate	global	prevalence	for	each.	One	study	suggests	that	T1D	is	most	
prevalent	in	Finland	(>60	per	100,000/year)	and	Sweden	(47	per	100,000/year),	whereas	
East	 Asia	 and	 native	 Americans	 have	 the	 lowest	 prevalence	 (approximately	 0.1–8	 per	
100,000/year)255.	Year	on	year,	the	average	age	of	onset	of	T1D	is	decreasing	along	with	




mellitus	 (NIDMM)	 or	 adult-onset	 diabetes.	 T2D	was	 considered	 a	 disease	 of	 the	 adult	
population,	but	recently	many	more	cases	have	been	identified	in	children258.			
In	T2D,	 the	 function	of	 the	β-cells	 is	 impaired	and/or	 the	body’s	 response	 to	 insulin	 is	
compromised,	 resulting	 in	hyperglycaemia.	Major	 contributing	 factors	are	excess	body	
weight	and	physical	inactivity;	over	80%	of	T2D	patients	are	obese	(BMI>30).	Other	risk	








diabetes	 have	 T2D	 it	 can	 be	 suggested	 at	 T2D	 prevalence	 closely	matches	worldwide	
diabetes	prevalence	figures,	shown	in	Table	1.5	from	the	latest	Risk	Factor	Collaboration	





















1980	 2014	 1980	 2014	
African	Region	 3.1	 7.1	 4	 25	
Region	of	the	Americas	 5	 8.3	 18	 62	
Eastern	Mediterranean	Region	 5.9	 13.7	 6	 43	
European	Region	 5.3	 7.3	 33	 64	
South-East	Asia	Region	 4.1	 8.6	 17	 96	
Western	Pacific	Region	 4.4	 8.4	 29	 131	










is	 important	 in	 the	 control	 of	 appetite,	 it	 tells	 the	 brain	when	 enough	 food	 has	 been	
consumed	relative	to	demand261.	The	ob/ob	mouse	cannot	produce	 leptin,	 therefore	 it	
has	 an	 uncontrolled	 appetite	 and	 rapidly	 increases	 in	 weight	 compared	 to	 a	 healthy	
mouse,	developing	hyperinsulinemia,	hyperphagia	and	insulin	resistance	at	3-4	weeks262.	





A	 significant	 limitation	 of	 mouse	 models	 is	 the	 lack	 of	 similarity	 for	 islet	 pathology	
observed	 in	 humans	 with	 T2D.	 In	 these	 mouse	 models,	 diabetes	 manifests	 as	 a	





specific	 RipCre	 promoter	 to	 knock	 out	 Fh1	 in	 the	 β-cells	 of	 the	 pancreas	 by	
recombination267.	 Mice	 lacking	 Fh1	 in	 pancreatic	 β-cells	 exhibit	 Hif1α-independent	


































A	 positive	 association	 between	 diabetes	 and	 cancer	 has	 been	 noted	 since	 the	 early	
nineteen	hundreds270.	Since	then,	a	significant	amount	of	epidemiological	work	has	been	



















for	 both	 diseases279–281.	 Notably,	 Yuhara	 and	 colleagues	 suggested	 that	 T2D	 is	 an	
independent	 risk	 factor	 for	CRC	once	confounding	variables	 including	obesity,	 smoking	
and	physical	exercise	are	removed111.	





Sharma	 et	 al.	 2005	 showed	 that	 CRC	 patients	 with	 T2D	 have	 more	 serious	
histopathological	features	such	as	deeper	tumour	invasion	and	more	advanced	staging124.	
Diabetic	 patients	 are	 also	 at	 increased	 risk	 of	 CRC	 recurrence	 compared	 to	 non-
diabetics287.	Conflicting	evidence	exists	 regarding	disease	 specific	 and	overall	mortality	
with	some	studies	showing	poor	survival	in	diabetics287	and	others	showing	this	apparent	
mortality	 increase	 is	 in	 fact	 due	 to	 increased	 age	 and	 co-morbidities288.	 A	 systematic	
review	on	this	topic	concluded	that	the	current	evidence	remains	inconclusive	since	most	
studies	fail	to	account	for	raised	BMI	and	the	effect	of	co-morbidities289.		




Insulin	 resistance	 and	 hyperinsulinemia	 are	 both	 common	 in	 T2D	 patients.	 Insulin	
resistance	 occurs	when	 the	 body	 is	 unable	 to	 respond	 to	 insulin	 resulting	 in	 elevated	
insulin	 in	 the	 blood.	 Insulin	 resistance	 is	 the	main	 driver	 of	metabolic	 syndrome	 (the	
medical	term	for	a	combination	of	T2D,	obesity	and	high	blood	pressure),	which	is	linked	
to	CRC290.	Hyperinsulinemia	 is	 the	 release	of	 too	much	 insulin	 relative	 to	 the	 levels	of	
blood	glucose291.	This	promotes	activation	of	cellular	pathways	mediated	by	insulin	and	




increased	 risk	 of	 CRC;	 insulin	 dose	 dependently	 promoted	 proliferation	 of	 normal	
colorectal	 epithelial	 cells	 in	 vivo292.	 There	 is	 also	 a	 direct	 correlation	 between	









damage	 and	mutations297	 such	 as	 insulin,	 fatty	 acids,	 IL-6,	 and	 plasminogen	 activator	
inhibitor	(PAI)-1,	adiponectin,	leptin,	TNF-α,	free	radicals	and	ROS.		





Cancer	 cells	 are	 known	 to	 depend	 on	 glycolysis	 for	 energy	 production	which	 requires	







Hyperglycaemia	 in	 insulin-independent	 tissues	 leads	 to	 an	 increase	 in	 substrates	 for	




Defects	 in	 mitochondrial	 morphology,	 fission,	 fusion,	 biogenesis	 and	 oxidative	
phosphorylation	are	associated	with	T2D304.	 Studies	have	been	 completed	on	heart305,	
skeletal,	adipose	and	renal306	tissue	as	these	are	the	most	relevant	for	complications	of	
T2D.	Mitochondria	 in	 skeletal	muscle	of	 T2D	compared	 to	non-diabetic	 individuals	 are	
smaller	 in	 size,	 at	 a	 lower	 density	 and	 have	 impaired	 function307,308.	 In	 adipose	 tissue,	
mitochondrial	dysfunction	leads	to	an	increase	in	fatty	acid	release	as	well	as	increased	
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into	 two	peptides,	one	 retaining	 the	N-terminal	mitochondrial	 targeting	 sequence	and	
one	that	is	released	into	the	cytoplasm.	In	the	mitochondria	FH	participates	in	the	TCA	
cycle	 (Figure	 1.7),	 where	 it	 catalyses	 the	 stereospecific	 hydration	 across	 the	 olefinic	
double	 bond	 in	 fumarate	 to	 form	 L-malate.	 In	 the	 cytosol,	 FH	 controls	 the	 levels	 of	
fumarate	 produced	 by	 the	 urea	 cycle	 (Figure	 1.11)	 and	 amino	 acid	 catabolism,	 by	
conversion	 to	malate	which	 in	 turn	provides	 increased	 substrate	 for	 the	generation	of	
cytosolic	NADPH	though	the	malic	enzyme	reaction168.	Cytosolic	FH	also	acts	as	a	DNA	




responsible	 for	 this	role315,316.	Loss	or	 inactivation	of	cytosolic	FH	causes	an	 increase	 in	
fumarate,	leading	to	genomic	instability	and	accumulation	of	HIF-1α		subunits317,318	(Figure	
1.12).	A	total	of	55	mutations	have	been	described	to	date	from	work	on	patients	with	
cutaneous	 leiomyoma,	 FH	 deficiency,	 hereditary	 leiomyomatosis	 and	 renal	 cell	 cancer	












glutamine	 to	 generate	 citrate	 and	malate	 by	 performing	 reductive	 carboxylation	 of	 α-
ketoglutarate	 to	 isocitrate.	 This	 process	 then	 provides	 the	 anabolic	 building	 blocks	
allowing	cell	proliferation320.	Additionally,	Fh1	deficient	mice	and	media	from	FH-deficient	
cell	 lines	 were	 found	 to	 excrete	 increased	 amounts	 of	 fumarate	 and	 arginosuccinate	








genes317,323,324.	 In	mice,	 inactivation	 of	 Fh1	 (murine	 FH)	 causes	 proliferative	 renal	 cyst	
development	and	activation	of	the	hypoxia	pathway325.	Using	HCT116	CRC	cells,	Yogev	et	
al.,	2010,	showed	that	irradiation	induced	more	cell	death	with	short	hairpin	RNA	(shRNA)	
























Fumarate	 is	 an	 oncometabolite332,333	 and	 can	 accumulate	 to	 millimolar	 levels	 in	 FH-
deficient	 tissues334.	 Increased	 levels	 of	 fumarate	 have	 been	 found	 in	 CRC	 patient	





DNA	 sequentially	 to	 5-hmC	 to	 5-formylcytocine	 to	 5-carboxylcytocine,	 leading	 to	 DNA	
methylation.	 2-OGDDs	 other	 functions	 are	 oxygen	 sensing	 (via	 HIF-1α),	 collagen	
maturation	and	regulation	of	translation.	Fumarate,	succinate	and	R-2-hydroxyglutarate	
are	 2-OGDD	 analogues	 and	 competitively	 inhibit	 several	 2-OGDDs	 with	 respect	 to	 2-
oxoglutarate.	 Fumarate	 competitively	 inhibits	 the	 2-OGDDs	 that	 catalyse	 HIF	 prolyl	
hydroxylation	leading	to	stabilisation	of	HIF-1α	and	activation	of	HIF-dependent	pathways	
including	glucose	metabolism332.		
Fumarate	 can	modify	 cysteine	 residues	 in	 proteins	 via	 an	 irreversible	 process	 termed	





dehydrogenase	 (GAPDH)	 in	 muscle	 of	 type	 1	 diabetic	 rats	 or	 preventing	 the	










in	 non-transformed	 cells341.	 The	 overall	 effect	 of	 2-SC	 modifications	 is	 currently	 not	





glucose	 versus	 5mM	glucose339.	Undifferentiated	 fibroblasts	 cultured	 in	 the	 same	high	
glucose	media	did	not	exhibit	 an	 increase	 in	 succination339	whereas	differentiated	3T3	
fibroblasts	do	exhibit	increased	succination	under	30mM	glucose310.	Frizzell	et	al.	showed	
that	3T3	cells	treated	with	30mM	glucose	compared	to	5mM	showed	significant	increase	






and	 succination.	 The	 conclusion	of	 the	 study	was	 that	 excess	 nutrients	 in	 the	 form	of	
glucotoxicity	creates	a	pseudo	hypoxic	environment	(high	NADH/NAD+)	which	drives	the	
increase	in	succination.		Subsequent	in	vivo	studies	indicate	that	increased	succination	in	



















is	achieved	by	diverting	amino	acids	 into	the	Krebs	cycle,	 thus,	maintaining	ATP	 levels,	
stabilising	NRF2	and	activating	the	NRF2	antioxidant	pathway.	
Fumarate	has	also	been	proven	to	have	a	role	as	an	epigenetic	modifier	in	the	context	of	
HLRCC349.	Fumarate	 inhibits	 the	Tet-mediated	demethylation	of	a	 regulatory	section	of	
the	 miRNA	 cluster	 mir-200ba429	 which	 is	 anti-metastatic,	 leading	 to	 promotion	 of	
epithelial	 to	mesenchymal	 transition	 (EMT)349.	 This	 in	 turn	 promotes	 cancer	 initiation,	
invasion	and	metastasis350.	
Interestingly,	 oral	 administration	 of	 fumarates	 such	 as	 dimethylfumarate	 (DMT)	 and	
mono-methylfumarate	 (MMF)	 improve	multiple	 sclerosis	 (MS)	 and	psoriasis351.	DMT	 is	
Food	and	Drug	Association	(FDA)	approved	for	the	treatment	on	MS	and	psoriasis352,353.	
Ghoreschi	et	al.	2011	describe	a	mechanism	which	results	in	glutathione	(GSH)	depletion	
and	 leads	 to	 induction	of	 type	 II	dendritic	cells	and	reduction	of	 IL-12	and	 IL-23354	and	
therefore	 improvement	 of	 psoriasis	 and	MS	 symptoms.	 Later	 it	 was	 found	 that	MMF	
which	 is	the	 immediate	metabolite	of	DMT	can	modify	KEAP1,	the	 inhibitor	of	NRF2	at	
cysteine	residue	151355.	DMF	treatment	has	also	been	shown	to	sensitise	cells	in	hypoxia	
to	radiation	treatment356.	Most	recently	DMF	has	been	shown	to	ameliorate	pulmonary	









The	key	 to	understanding	 these	 roles	of	 fumarate	as	either	an	oncometabolite	or	as	a	









as	 PHDs	 leading	 to	 stabilisation	 of	 HIF-1α	 and	 activation	 of	 HIF-dependent	 pathways	
including	glucose	metabolism332.	(B)	Epigenetic	changes.	Fumarate	can	inhibit	TETs	and	
KDMs	 leading	 to	 alterations	 in	 gene	 expression360.	 (C)	 Succination.	 The	 irreversible	
generation	of	a	thioether	bond	between	fumarate	and	the	cysteine	sulphydryl	group	to	
create	2-SC337.	2-OGDD,	2-oxoglutarate-dependent	dioxygenase;	PHD,	prolyl	hydroxylase;	
























regulates	 food	 intake	 and	 energy	 expenditure.	 Ob/ob	 mice	 exhibit	 a	 hyperphagia,	 a	
transient	 diabetes-like	 syndrome	 of	 hyperglycaemia	 and	 glucose	 intolerance,	 elevated	
plasma	insulin,	subfertility,	impaired	wound	healing	and	increased	hormone	production	
from	 the	 pituitary	 and	 adrenal	 glands,	 as	 well	 as	 being	 hypo	 metabolic	 and	
hypothermic365.	To	study	environmentally-induced	obesity	they	fed	the	F1	mice	either	a	
45%	 fat	 diet	 or	 a	 control	 10%	 fat	 diet	 as	 adults.	 	 They	 concluded	 that	 homozygous	
mutation	 in	 the	ob	 gene	 significantly	 increased	 the	 number	 of	 spontaneous	 intestinal	





properties	 of	 diabetes	 alongside	 spontaneous	 development	 of	 CRC	 in	 the	 absence	 of	
obesity.	However,	this	is	unlikely	to	be	possible	due	to	the	inherent	short	lifespan	of	mice.	
































• The	 number	 of	 mitochondria	 will	 be	 highest	 in	 CRC	 cells	 held	 in	 normoxia	
compared	 to	 hypoxia	 and	 cultured	 in	 no	 glucose	 compared	 to	 glucose	 and	





reduced	 with	 cetuximab	 treatment	 and	 DUOX2	 expression	 is	 increased	 with	
oxaliplatin	treatment,	and	reduced	with	cetuximab	treatment.		
• CRC	 xenografts	 treated	 with	 cetuximab	 and	 oxaliplatin	 would	 have	 more	
proliferating	cells.		
My	aims	were:	
• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	2-SC.	
• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	FH.	
• To	examine	whether	KRAS/BRAF	mutation	in	CRC	is	linked	to	2-SC	staining	score.	










• Analyse	DUOX2	 and	DUOXA2	 gene	 expression	 by	 RT-PCR,	 and	 DUOX2	 protein	
expression	by	IHC.		








Human	 normal	 gut	 mucosa	 and	 CRC	 samples	 were	 obtained	 from	 The	 Royal	 London	
Hospital	 Pathology	Department.	 Ethical	 approval	 for	 this	 study	was	obtained	 from	 the	
local	Human	Research	Ethics	Committees	(REC	reference	13/LO/1271).		
2.1.2	Immunohistochemistry	to	detect	succination	








Whitechapel,	 London,	UK).	RF	was	blinded	 to	 the	diabetic	 status	of	 the	patients	when	
scoring	 the	 stained	 sections.	 Scoring	 was	 based	 on	 a	 standard	 scoring	 protocol:	
percentage	 of	 epithelial	 cells	 at	 each	 of	 three	 staining	 intensity	 levels	 (1-	 3;	 low,	
immediate	and	strong)	and	a	weighted	score	generated	using	the	formula	(1x1	+	2x2	+	
3x3).	Analysis	involved	paired	matched	normal	and	tumour	values.	The	positive	controls	













































offspring	 (see	Table	2.2	 for	breeding	details).	 Female	Fh1flox/flox	RipCre	CAGFH	mice	had	 loxP	
sites	in	both	Fh1	alleles	and	were	RipCre	positive;	the	rat	insulin	II	gene	promoter	controls	
cre	 recombinase	creating	a	 conditional	 knockout	of	Fh1	 in	 the	β-cells	of	 the	pancreas.	
These	mice	were	also	globally	positive	for	CAGFH	(human	cytoplasmic	FH,	which	ensures	
that	 the	FH	 is	expressed	 in	every	cell)	 to	enable	 females	to	carry	offspring	to	 full	 term	





at	 55°C.	 DNA	 was	 precipitated	 using	 iso-propanol	 and	 re-suspended	 in	 nuclease	 free	

















































































































































































Mice	 were	 sacrificed	 via	 a	 schedule	 1	 procedure	 60-90	 days	 after	 birth	 or	 when	

















the	 schedule	 in	 Table	 2.5	 using	 large	 moulds	 (Simport,	 11601000	 X1000	 Base	 mould	





detected	 with	 anti-lysozyme	 (Dako,	 #EC	 3.2.1.17)	 used	 at	 1:500	 after	 5	 minutes	










































ice	 then	 shipped	 to	 the	 Institute	 for	Advanced	Biosciences	 in	 Japan	 for	 CE-TOF/MS	 as	
described	previously371,372.	
2.2.9	Statistics		 	








(who	 also	 validated	 the	 cell	 lines)	 Wellcome	 Institute	 for	 Human	 Genetics,	 Oxford	
University,	and	were	maintained	in	Dulbecco’s	modified	Eagle’s	Medium	(DMEM)	(Gibco,	
#11966),	with	10%	fetal	bovine	serum	(FBS)	(Labtech,	#FB-1001T/500),	171μM	penicillin	
(Sigma,	 #P4333),	 172μM	 streptomycin	 (Sigma,	 #P4333),	 2mM	 L-glutamine	 (GE	
Healthcare,	 #M11-006)	 and	 either	 25mM,	 5mM	 or	 0mM	 glucose	 (Sigma,	 #G7021)	 as	
detailed	below.		
I	decided	to	reduce	[glucose]	in	the	media	slowly	over	a	period	of	3	months:	first,	from	
25mM	 to	 12.5mM;	 then	 in	 12.5mM	 glucose	 until	 their	 doubling	 time	was	 stable.	 The	
process	 was	 repeated	with	 10mM,	 7.5mM	 and	 5mM	when	 the	 cells	 were	 banked	 by	
storage	in	liquid	nitrogen.	The	glucose	was	reduced	further	to	2.5mM	and	finally	0mM	in	
the	 same	way;	 the	 cells	 which	 grew	 at	 0mM	 glucose	were	 banked.	 Once	 the	 desired	
[glucose]	was	established,	which	was	25mM,	5mM	and	0mM,	the	cells	were	cultured	for	
a	 further	 8	 passages	 before	 using	 the	 cells	 for	 experimentation	 to	 ensure	 continued	
stability	of	doubling	time.	
Fh1	 WT	 and	 KO	 MEFs	 were	 a	 gift	 from	 Dr	 Julie	 Adam,	 Oxford	 Centre	 for	 Diabetes,	
Endocrinology	 and	 Metabolism	 and	 were	 maintained	 in	 DMEM	 containing	 10%	 fetal	
bovine	serum	(FBS),	171μM	penicillin,	172μM	streptomycin,	2mM	L-glutamine	and	25mM	
glucose.	All	 cell	 lines	were	kept	at	37°C	under	a	humidified	atmosphere	containing	5%	
CO2,	 and	 20.9%	O2.	 A	 1%	 and	 0.2%	O2	atmosphere	was	 provided	 by	 an	 INVIVO2	1000	





concentration	 was	 determined	 by	 the	 PierceTM	 BCA	 Protein	 Assay	 (ThermoFisher,	
#23225).	Equal	amounts	of	protein	were	added	to	4-12%	Bis-Tris	polyacrylamide	gels	(Life	
	 102	
Technologies).	Proteins	were	 transferred	 to	a	PVDF	membrane	using	 the	Pierce	Power	
Blotter	 (Life	Technologies).	Membranes	were	blocked	 in	5%	dry-milk	 in	PBS	containing	
0.1%	Tween-20	(Sigma)	(PBS-T)	for	1	hour	at	room	temperature.	After	washing	in	PBS-T,	
membranes	were	 incubated	with	 the	 appropriate	 primary	 antibody	 (Table	 2.6)	 at	 4°C	
overnight.	After	washing	with	PBS-T,	membranes	were	 incubated	with	the	appropriate	
horseradish	peroxidase	(HRP)-conjugated	secondary	antibody	at	room	temperature	for	1	
hour	 (see	 Table	 2.6).	 Proteins	 were	 detected	 using	 Pierce	 ECL	 Plus	 Western	 Blotting	
Substrate	(Thermo,	#32106).	
2.3.3	Viability	assay	
Cells	 were	 plated	 in	 6	 well	 plates	 and	 kept	 at	 37°C	 under	 a	 humidified	 atmosphere	






Fumarate	 (fmol/cell)	 was	 determined	 by	 CE-TOF/MS	 analysis	 by	 Professor	 Tomoyoshi	
Soga	(Keio	University,	Japan).	DLD1,	HT55	and	SW837	cell	lines	were	cultured	with	25mM	
glucose	DMEM	and	held	under	20.9%,	1%	or	0.2%	O2	for	48	hours.	Cells	were	then	washed	
two	times	 in	5%	Mannitol	 (Wako,	 Japan)	and	harvested	 in	methanol	containing	25mM	





CO2	 and	 20.9%	 O2.	 At	 24	 hours,	 the	 cells	 were	 placed	 at	 37°C	 under	 a	 humidified	
atmosphere	 containing	 5%	 CO2,	 and	 either	 20.9%	 or	 0.2%	O2.	 At	 72	 hours,	 cells	were	
washed	with	PBS	and	harvested	with	TrypLETM	Express	 (Invitrogen,	#12605-010).	1x106	
	 103	






































CO2	 and	 20.9%	 O2.	 At	 24	 hours,	 the	 cells	 were	 placed	 at	 37°C	 under	 a	 humidified	
atmosphere	 containing	 5%	 CO2,	 and	 either	 20.9%	 or	 0.2%	O2.	 At	 72	 hours,	 cells	were	
washed	with	PBS	and	the	flask	was	put	immediately	at	-80°C	for	at	least	24	hours.	Cells	
were	 thawed	 on	 ice,	 harvested	 with	 Hepes-KOH	 pH7.6	 with	 phosphatase	 inhibitors,	
sonicated	and	stored	at	 -80°C.	Samples	were	 incubated	with	a	 reaction	mix	containing	
10μM	NAD+	(Sigma,	#N7004),	1M	KH2PO4	(Sigma),	1M	MgCl2	(Sigma),	50mM	Hepes-KOH	
pH7.6	 (Sigma),	 10mM	 glutamic	 acid	 (Sigma,	 #G8415),	 malate	 dehydrogenase	 (Sigma,	
#M1567)	and	glutamic	oxaloacetate	transaminase	(Sigma,	#10105554001)	for	10	mins	at	
37°C.	30mM	fumeric	acid	(Sigma,	F8509)	was	then	added	to	the	mix.	Fluorescence	was	
measured	every	40	 seconds	at	 excitation	340nm,	emission	460nm	 for	15	minutes	 and	
corresponded	to	NADH	produced.	NADH	standards	were	made	up	fresh	(Sigma,	#N8129).		
2.3.7	Immunostaining		
Cells	 were	 plated	 in	 96-well	 plates	 and	 kept	 at	 37°C	 under	 a	 humidified	 atmosphere	
containing	 5%	 CO2	 and	 20.9%	O2.	 At	 24	 hours,	 the	 cells	were	 placed	 at	 37°C	 under	 a	
humidified	atmosphere	containing	5%	CO2,	and	either	20.9%	or	0.2%	O2.	At	72	hours,	cells	
were	washed	with	PBS	and	fixed	with	4%	paraformaldehyde,	followed	by	0.1%	Triton	X	
permeabilisation	 and	 blocking	 with	 0.25%	 bovine	 serum	 albumin	 (BSA),	 followed	 by	
antibody	incubations	(Table	2.7).		











































































medium	was	 changed	 to	 XF	 assay	medium	 (Agilent)	 containing	 25mM,	 5mM	or	 0mM	
glucose,	1mM	pyruvate,	2mM	glutamine,	and	the	cells	were	incubated	at	37°C	for	1	hour.	
Steady-state	 (baseline)	 oxygen	 consumption	 rates	 and	 extracellular	 acidification	 rates	
were	 measured	 using	 a	 XF24	 extracellular	 flux	 analyser	 (Agilent).	 Addition	 of	 1μM	
oligomycin	was	used	to	evaluate	the	amount	of	ATP	produced	by	the	mitochondria	of	the	
cells	by	inhibiting	ATP	synthase	(complex	V);	addition	of	0.6μM	FCCP	was	used	to	evaluate	
the	 maximal	 oxygen	 consumption	 rate	 by	 uncoupling	 oxygen	 consumption	 from	 ATP	
production;	addition	of	0.5μM	rotenone	and	antimycin	A	was	used	to	measure	the	spare	
respiratory	capacity	of	 the	cell	by	 inhibiting	complex	 I	and	 III	of	 the	electron	transport	
chain	respectively.		
2.3.10	Statistics		






































cells	 in	 200uL	 saline	 on	 a	 single	 flank.	 Once	 tumours	were	 between	 200-300mm3	 the	
dosing	 schedule	 was	 initiated.	 Mice	 were	 randomised	 into	 four	 treatment	 arms;	 1)	













RNA	was	extracted	using	miRNeasy	 kit	 (Qiagen)	 according	 to	manufacturer’s	 protocol.	
RNA	 concentrations	 were	 determined	 using	 a	 Nanodrop	 Technologies	
spectrophotometer.	 A	 tissue	 ruptor	 instrument	 (Qiagen)	 was	 used	 to	 assist	 with	
homogenisation	 of	 tissue.	 RNA	 samples	 were	 reverse-transcribed	 using	 a	 Reverse	
Transcriptase	 kit	 (ABI)	 and	 reverse	 transcription	 (RT)	 products	 were	 incubated	 with	
selected	 TaqMan	 assays	 and	 TaqMan	 Universal	MasterMix	 (Applied	 Biosystems)	 on	 a	
	 110	
7500	 Fast	 System	 RealTime	 PCR	 cycler	 (Applied	 Biosystems),	 according	 to	 the	











at	 room	 temperature	 -	 rabbit	 anti-human	 Ki67	 at	 1:1000	 dilution	 (Abcam,	 #ab92742);	
rabbit	 anti-human	 cleaved	 caspase	 3	 at	 1:400	 (Cell	 Signaling	 #9664);	 DUOX2	 at	 1:50	
dilution	 (Millipore,	 #MABN787).	 Sections	 were	 then	 incubated	 with	 a	 biotinylated	








dewaxed	 and	 rehydrated	 in	water	 then	 incubated	with	 Pre-treatment	 1	 buffer	 for	 10	
minutes	at	room	temperature.	Next	slides	were	boiled	in	Pre-treatment	2	buffer	for	15	
minutes,	followed	by	incubation	with	Pre-treatment	3	buffer	for	30	minutes	at	40˚C.	Then	
slides	 were	 incubated	 with	 the	 probe	 for	 2	 hours	 at	 40˚C,	 followed	 by	 successive	







































in	 adipose	 and	 skeletal	 muscle	 cells	 of	 diabetic	 animal	 models341,346.	 Its	 functional	
consequences	 include	 loss	of	activity	of	 the	mitochondrial	Krebs	cycle	aconitase345	and	
the	glycolytic	enzyme	glyceraldehyde	3-phopshate	dehydrogenase	(GAPDH)338.		
To	date,	 the	only	 cancer	 in	which	protein	 succination	has	 been	described	 is	HLRCC374.	
HLRCC	patients	have	a	loss	of	function	mutation	in	FH	that	results	in	millimolar	levels	of	
fumarate,	 which	 leads	 to	 succination330.	 Fumarate	 is	 a	 member	 of	 the	 TCA	 cycle	 in	
mitochondria,	where	it	is	converted	to	malate	by	FH.	Fumarate	is	also	produced	by	the	
urea	cycle	and	amino	acid	catabolism	in	the	cytoplasm;	excess	fumarate	here	is	mopped	
up	 by	 cytoplasmic	 FH.	 Other	 known	 roles	 for	 fumarate	 are	 promotion	 of	 cancer	 cell	
survival	 by	 stabilisation	 of	 HIF-1α	 by	 competitively	 inhibiting	 2-OGDDs	 leading	 to	
activation	of	HIF-dependent	pathways	such	as	glucose	metabolism332.	Fumarate	can	also	
reduce	 DNA	 methylation	 by	 inhibiting	 TET	 5-mC	 2-OGDDs.	 Fumarate	 has	 since	 been	
described	 as	 an	 oncometabolite375.	 Fumarate	 is	 elevated	 in	 CRC	 tissue	 compared	 to	
matched	normal335	 and	 the	 functional	 consequences	of	 succination	might	 explain	why	
those	 with	 T2D	 who	 present	 with	 CRC	 have	 more	 invasive	 CRC,	 as	 well	 as	 a	 poorer	
outcome	due	to	 loss	of	activity	of	key	proteins	within	the	cell.	Moreover,	mutations	 in	
KRAS	and	BRAF	are	found	in	approximately	40%	and	10%	of	CRC	cases	respectively376,377,	













• To	 test	 a	 panel	 CRC,	 adenoma	 and	 normal	 tissue	 from	 non-diabetic	 and	 T2D	
individuals	for	the	presence	of	2-SC.	





















ND	 T2D	 ND	 T2D	 ND	 T2D	
Total	no.	of	samples		 67	 26	 23	 7	 57	 25	
Percentage	(%)	of	samples	
with	succination	evidence	





IHC	 for	 2-SC	 was	 performed	 on	 matched	 normal	 intestinal	 mucosa	 and	 CRC	 patient	
samples;	58	from	non-diabetic	patients	and	25	from	T2D	patients	(Table	3.1,	Figure	3.1).	
I	 identified	 and	 sourced	 the	 patient	 blocks	 from	The	Royal	 London	hospital	 pathology	
archive,	 collated	 and	 analysed	 the	 data.	 IHC	 was	 carried	 out	 by	 Julie	 Adam	 using	 a	
validated	 antibody	 that	 detects	 2-SC	 motifs342	 that	 was	 gifted	 by	 Norma	 Frizzell	 (the	
antibody	 is	 not	 commercially	 available	 and	 Julie	 Adam	 holds	 the	 material	 transfer	
agreement)	 (Chapter	 2,	 Section	 2.1.2).	 The	 sections	 were	 scored	 by	 Roger	 Feakins	
(consultant	pathologist)	according	to	protocol	given	in	Chapter	2,	Section	2.1.3.		
2-SC	 was	 significantly	 elevated	 in	 CRC	 tissue	 compared	 to	 matched	 normal	 tissue	




was	 significantly	 higher	 in	 CRC	 tissue	 from	 T2D	 patients	 compared	 to	 non-diabetic	
patients	(p=0.001).		








amount	 of	 2-SC.	 This	 association	 between	 cancer,	 T2D	 and	 succination	 has	 not	 been	
shown	before.		 	
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CRC	 tissue,	 spilt	 into	non-diabetic	 (ND)	 (n=57)	and	T2D	 (n=25)	patients.	 (C)	CRC	minus	







	 Number	 Normal	 CRC	 CRC	-	Normal	
Total		 83	 20.23±2.06	 84.49±5.22	 64.27±5.81	
Non-diabetic		 57	 19.45±2.39		 75.05±5.55	 55.61±6.55	










diabetic	 status.	 The	 results	 must	 be	 interpreted	 with	 caution	 until	 this	 study	 can	 be	
repeated	with	larger	numbers.		
The	amount	of	2-SC	was	 significantly	elevated	 (p<0.0001,	unpaired	 t-test)	 in	 adenoma	






When	 the	2-SC	 score	of	 the	normal	 tissue	was	 taken	away	 from	the	2-SC	 score	of	 the	
adenoma	 tissue,	 there	 was	 no	 significant	 difference	 between	 non-diabetic	 and	 T2D	




higher	 in	 the	adenoma	compared	to	 the	matched	normal	 in	 in	87.50%	of	patients	and	
lower	in	12.50%.	
These	results	suggest	that	succination	is	present	in	elevated	levels	at	the	early	stages	of	








T2Ds.	 IHC	 was	 carried	 out	 on	 tissue	 sections	 with	 2-SC	 antibody.	 Sections	 were	 then	
scored	by	Roger	Feakins	a	consultant	pathologist.	(A)	2-SC	score	of	matched	normal	and	
adenoma	 tissue	 (n=26).	 Unpaired	 two-tailed	 t-test	 was	 performed.	 (B)	 2-SC	 score	 of	
matched	normal	and	adenoma	tissue,	 spilt	 into	non-diabetic	 (n=19)	and	diabetic	 (n=7)	







	 Number	 Normal	 Adenoma	 Adenoma	-	Normal	
Total		 30	 16.17±2.27	 65.80±7.02	 46.63±7.41	
ND		 23	 15.76±2.84		 72.00±8.18	 56.24±8.81	










adenoma	 tissue	 and	 CRC	 tissue	 (p<0.0001)	 (Figure	 3.4.A,	 Table	 3.4,	 A.3.7,8)	 and	 no	
significant	difference	was	observed	between	adenoma	and	CRC	tissue.	In	T2D	patients,	2-
SC	 was	 also	 significantly	 lower	 in	 normal	 tissue	 when	 compared	 to	 adenoma	 tissue	










Figure	3.4.	 2-SC	 score	 in	 total	normal,	 adenoma	and	CRC	 tissue	 in	non-diabetics	 and	
T2Ds.	 IHC	 was	 carried	 out	 on	 tissue	 sections	 with	 2-SC	 antibody.	 Sections	 were	 then	
scored	by	a	pathologist.	(A)	2-SC	score	of	normal	(n=94),	adenoma	(n=30)	and	CRC	tissue	
(n=83).	One-way	ANOVA	was	 performed.	 (B)	 2-SC	 score	 of	 normal,	 adenoma	and	CRC	
tissue,	 spilt	 into	 non-diabetic	 (normal	 n=67,	 adenoma	 n=23,	 CRC	 n=57)	 and	 diabetic	








	 Normal	 Adenoma	 CRC	 Normal	 Adenoma	 CRC	
Total	 94	 30	 83	 19.35±1.87	 67.55±6.92	 84.49±5.22	
ND	 67	 23	 57	 18.37±2.11		 72.00±8.18	 75.05±5.55	
T2D	 27	 7	 26	 21.76±3.91	 50.50±10.98	 105.19±10.46	
	





Tissue	 All	 T2D	 ND	
Adenoma		 86.67%	 71.43%	 91.30%	





































Fumarate	 generates	 2-SC,	 therefore,	 if	 there	 is	 an	 increased	 level	 of	 2-SC,	 it	 could	 be	
assumed	that	 fumarate	 is	also	elevated.	Fumarate	 is	a	metabolite	of	the	TCA	and	urea	










product	 for	 BRAF	 (Figure	 3.6.A,B).	 PCR	 product	 was	 cleaned	 and	 sent	 for	 Sanger	











Location	 Codon	12	 Codon	13	 V600E	







Figure	 3.6.	 KRAS/BRAF	 PCR	 and	 Sanger	 sequencing.	DNA	 was	 extracted	 from	 frozen	
tissue	or	paraffin	sections.	PCR	was	performed	using	Qiagen	Master	Mix	then	run	on	a	2%	
agarose	gel	and	visualised	using	a	Chemi	Doc	(Chapter	2,	Section	2.1.5).	PCR	product	was	
cleaned	 using	 ExoSAP-IT	 (Qiagen)	 and	 sent	 for	 Sanger	 sequencing	 (GATC	 biotech).	 (A)	








diabetic	 status	 had	 a	 significant	 effect	 on	 2-SC	 score	 (p=0.0034)	 (Figure	 3.7.B)	 (Table	







































	 Number	 CRC	 CRC	-	Normal	
	 WT	 Mutant	 WT	 Mutant	 WT	 Mutant	





























Metabolites	 such	as	 fumarate	are	not	widely	quantitated	 in	 tissue	due	 to	high	 cost	of	
current	methods	as	well	as	a	lack	of	effective	methodology.	Metabolites	are	often	highly	
polar,	non-volatile	and	have	poor	detectability	making	analysis	difficult.	Chan	et	al.	used	





patient	samples385.	Both	of	 these	studies	showed	a	 reduction	 in	TCA	cycle	metabolites	
which	links	well	with	Otto	Warburg’s	theory	of	reduced	mitochondrial	metabolism386.		
Hirayama	et	al.	used	capillary	electrophoresis	TOFMS	 (CE-TOFMS),	which	 they	argue	 is	
more	suited	to	metabolism	analysis	due	to	its	high	resolution	and	ability	to	simultaneously	





(Figure	 3.2.A).	My	work	 has	 also	 shown	elevated	 succination	 in	 the	 early	 stage	 of	 the	










Interestingly,	 succination	 was	 not	 significantly	 elevated	 in	 normal	 tissue	 from	 T2D	








found	 to	 have	 elevated	 succination	 as	well	 as	 adipocytes	 treated	with	 30mM	 glucose	
versus	5mM	glucose339	in	vitro.	Interestingly,	undifferentiated	fibroblasts	cultured	in	the	
same	 high	 glucose	 media	 did	 not	 exhibit	 an	 increase	 in	 succination339	 whereas	
differentiated	3T3	 fibroblasts	do	exhibit	 increased	succination	under	30mM	glucose310.	
Frizzell	et	al.	2012	showed	that	3T3	cells	treated	with	30mM	glucose	compared	to	5mM	
also	 showed	 significant	 increases	 in	 cellular	 ATP/adenosine	 diphosphate	 (ADP),	
NADH/NAD+,	mitochondrial	membrane	 potential	 and	 cellular	 fumarate	 concentration.	
This	 was	 postulated	 to	 an	 increase	 in	 NADH/NAD+	 ratio	 resulting	 in	 the	 inhibition	 of	
NAD+-dependent	 dehydrogenases.	 Cellular	 fumarate	 and	 succination	 was	 decreased	




Mitochondrial	 function	 is	 known	 to	 be	 deregulated	 in	 cancer387	 and	 that	 increased	
glycolysis	is	a	feature	of	cancer.	Therefore,	it	could	be	suggested	that	glucotoxicity-driven	
mitochondrial	stress	exists	within	CRC	which	leads	to	elevated	fumarate	and,	therefore,	
elevated	 succination.	 In	 turn,	 the	 glucotoxicity-driven	 mitochondrial	 stress	 is	 further	
elevated	in	patients	with	T2D,	leading	to	higher	levels	of	succination.	Unfortunately,	I	was	
unable	 to	 determine	 the	 diabetic	 treatment	 for	 the	 majority	 of	 the	 CRC	 patients,	 as	
hospital	 records	 are	 incomplete.	 Nevertheless,	 it	 would	 be	 interesting	 to	 study	 the	





suggests	 that	 FH	 is	 upregulated	 in	 conjunction	with,	 or	 as	 a	 consequence	 of	 elevated	
fumarate,	 but	 is	 unable	 to	 remove	 the	 excess	 fumarate.	 FH	 may	 be	 dysfunctional.	





suggests	 that	 at	 low	 fumarate	 concentrations	 (<1mM)	 the	 enzyme	 shows	 Michaelis-
Menten	kinetics;	at	0.001-0.033M	allosteric	activation	of	the	enzyme	by	binding	to	site	B	
is	observed;	at	0.1M	and	above	fumarate	actually	inhibits	FH390.	Therefore,	it	could	be	that	
fumarate	 itself	 is	 inhibiting	 the	 action	 of	 FH,	 leading	 to	 further	 increases	 in	 fumarate.	
Hirayama	et	al.	showed	that	the	fumarate	concentration	in	colon	tumour	was	around	an	





conformation,	 constitutively	 presenting	 a	 docking	 surface	 for	 RAF	 kinases391.	 BRAF	
mutations	 are	 found	 in	 10%	 of	 CRCs,	 and	 are	 most	 likely	 to	 be	 a	 V600E	 amino	 acid	
substitution,	 although	 other	 mutations	 at	 codon	 600	 or	 neighbouring	 positions	 are	
documented29.	 The	 presence	 of	 these	mutations	 in	 our	 cohort	 is	 in	 accord	with	 these	
results	 and	 were	 selected	 for	 examination	 as	 they	 are	 amongst	 the	 most	 prevalent	
mutations	found.		
Although	the	use	of	KRAS	and	BRAF	mutation	status	as	a	predictive	biomarker	of	response	
to	 anti-EGFR	 therapy	 is	well	 supported,	 there	 are	 inconsistencies	within	 the	 literature	
regarding	the	association	between	KRAS	and	BRAF	mutations	and	CRC	survival.	There	are	
discrepancies	related	to	specific	mutations,	age,	stage	at	diagnosis	and	treatment.	The	












respiration	were	not	 affected394.	 It	was	 also	 shown	 that	 the	WT	KRAS	CRC	 cells	which	
survived	4	days	of	culture	with	0.5mM	glucose	increased	their	mutation	rate	of	KRAS	to	











is	 associated	 with	 increased	 levels	 of	 both	 GLUD1	 and	 SLC25A13	 (a	 mitochondrial	
aspartate-glutamate	carrier)397.		







Currently,	 there	 is	 no	 literature	 which	 link	 KRAS	 or	 BRAF	mutation	 to	 an	 increase	 in	
succination.	 This	 study	 hypothesised	 that	 presence	 of	 KRAS	 or	 BRAF	mutation	 would	
increase	succination	via	increased	use	of	the	TCA	cycle.	The	data	show	that	there	is	no	
significant	effect	of	KRAS	or	BRAF	mutation	status	on	2-SC	score.	However,	 there	 is	an	
increase	 in	2-SC	 score	 in	 samples	 from	patients	with	 T2D	and	KRAS	or	BRAF	mutation	
combined	 compared	 to	 samples	 from	 non-diabetic	 KRAS	 or	 BRAF	WT	 patients.	 This	







match	 normal	 tissue.	 Succination	 in	 CRC	 is	 further	 increased	 in	 the	 presence	 of	 T2D.	
Additionally,	 the	 2-SC	 staining	 was	 non-uniform	 across	 tumours,	 underlining	 the	
metabolic	heterogeneity	of	CRC	tissue.	T2D	patients	with	KRAS/BRAF	mutation	exhibit	a	
further	 increase	 in	 succination	 compared	 to	 T2D	 patients	 with	 WT	 KRAS/BRAF.	 The	
possibility	 of	 a	 link	 between	 2-SC	 score	 and	 patient	 prognosis	 requires	 further	
investigation	 and	would	 be	 an	 interesting	 avenue	 to	 pursue.	 The	 functional	 effects	 of	
succination	are	likely	to	be	wide-spread	and	would	take	more	time	to	investigate	through	
collaboration.	Additionally,	the	role	of	FH	in	CRC	patients	should	be	further	investigated	
(Chapter	8,	Section	8.1).	Here,	 I	 found	FH	 is	present	 in	CRC	tissue	at	an	elevated	 level,	
although	 it	 remains	 to	be	determined	 if	FH	 is	 fully	active	or	 inhibited	by	high	 levels	of	












RipCre	 CAGFH);	 	 models	 were	 introduced	 in	 Chapter	 1,	 Section	 1.10	 and	 Section	 1.12,	
respectively.	 The	 breeding	 steps	 are	 outlined	 in	 Figure	 4.1	 and	 described	 below;	 for	
further	details,	refer	to	Chapter	2,	Section	2.2.1.	All	animals	used	were	backcrossed	on	a	
C57BL/6J	 background	 at	 least	 3	 times	 and	 littermate	 controls	 were	 used.	 Animal	
experiments	were	conducted	in	accordance	with	the	UK	Animals	Scientific	Procedures	Act	
(1986)	and	University	of	Oxford	local	ethical	guidelines	under	the	direction	of	Dr	J	Adam.	
The	novel	diabetic	model	 (Fh1flox/flox	RipCre	CAGFH	mice268	 (designated	Fh1βKO	mice	 for	 this	










Fh1βKO	 mice	 become	 very	 diabetic	 by	 approximately	 16	 weeks	 of	 age	 (with	 a	 blood	
glucose	of	>33.3mM)268	so	it	is	not	possible	to	use	female	Fh1βKO	for	breeding	purposes.	
Also,	 the	pups	of	 a	diabetic	mother	become	diabetic	much	 faster	 To	enable	breeding,	
Fh1βKO	mice	were	crossed	with	mice	stably	expressing	the	cytoplasmic	form	of	human	
FH,	 under	 the	 CAG	 promoter	 (designated	 FHcyt	 for	 this	 thesis)330	 to	 generate	
	 140	





then	 intercrossed	 with	 male	 Apc1322T	 mice	 (designated	 1322	 for	 this	 thesis).	 Female	
Apc1322T	mice	cannot	be	used	for	breeding	purposes	because	the	mice	become	sick	due	to	
the	polyp	burden	and	anaemia.	
The	addition	of	cytoplasmic	FH	allowed	 the	 role	of	FH	 in	 tumourigenesis	 to	be	 further	
scrutinised.	Cytoplasmic	FH	has	a	role	in	the	urea	cycle,	and	it	can	also	translocate	to	the	
nucleus	to	aid	repair	of	double	strand	breaks	in	DNA399.	It	is	unclear	if	the	high	levels	of	
FH	 shown	 in	 the	 human	 CRC	 samples	 are	 cytoplasmic,	 nuclear	 and/or	 mitochondrial.	











non-diabetic	mice	 and	mice	with	overexpression	of	 FH	will	 have	 fewer	 and/or	 smaller	
polyps.	I	also	hypothesised	that	diabetes	may	alter	the	cellular	profile	of	the	gut.		
4.1.2	Aims	











Table	 4.1	 along	with	 their	 denoted	 name,	 diabetic	 and	 polyp	 phenotype	 and	 purpose	
(Figure	 4.1).	 All	 the	 genotypes	 were	 compared	 in	 the	 following	 investigations	 in	 this	










































FHcyt	1322	 FH	 overexpressed	 in	 the	
cytoplasm	 of	 all	 somatic	
cells,	Apc1322	allele	
	
No	 Yes		 To	 study	 the	 effect	 of	
overexpression	 of	 FH	 in	














No	 Fh1	 in	 β-cells,	 FH	
overexpressed	 in	 the	





Yes	 To	 study	 the	 effect	 of	
pre-diabetic	 blood	
glucose	 coupled	 with	
overexpression	 of	 FH	 in	








No	 Fh1	 in	 β-cells,	 Apc1322	
allele	
	
































Figure	 4.2.	Mom-1	 genotyping.	 (A)	 Schematic	 representation	 of	 BamH1	 digestion	 of	
Mom-1	alleles.	The	Mom-1S	allele	does	not	have	a	BamH1	restriction	site	and,	therefore,	
the	PCR	product	 remains	 intact,	whereas	 the	Mom-1R	allele	PCR	product	has	a	BamH1	
restriction	site,	which	is	digested	by	BamH1	restriction	enzyme	to	give	a	400bp	and	100bp	






It	 was	 necessary	 to	 determine	 that	 the	 blood	 glucose	 of	 the	 mice	 generated	 by	 the	
crossing	Fh1βKO	FHcyt	mice	with	Apc1322T	mice	was	as	predicted.	It	was	unlikely	that	the	
Apc1322T	allele	would	interfere	with	the	diabetic	phenotype	generated	by	the	presence	of	




As	 expected,	 Fh1βKO	 and	 Fh1βKO	 1322	mice	 had	 significantly	 higher	 blood	 glucose	
compared	to	all	other	genotypes	(p<0.0001)	(Figure	4.3,	Table	A.4.2,3);	Fh1βKO	mice	were	
strongly	diabetic	with	 the	maximum	read	on	the	blood	glucose	monitor	 (33.3	mmol/L)	
reached	 for	 71%	 (10	 out	 of	 14)	 of	 these	mice.	 Fh1βKO	 1322	mice	 had	 a	 lower	 blood	









































Polyps	 and	 adjacent	 normal	 tissue	 samples	 from	each	mouse	 genotype	with	 the	1322	












































to	 non-diabetic	 animals.	 The	 gut	 is	 very	 delicate	 once	 removed	 from	 the	 body,	 so	 to	
preserve	 the	 architecture	 the	 tissue	was	 fixed	 immediately	 as	 described	 in	 Chapter	 2,	






When	 comparing	 the	 length	 of	 the	 entire	 gut,	 the	Fh1βKO	mice	was	 the	 longest,	 and	
significantly	longer	than	the	guts	of	the	Fh1βKO	FHcyt	(p=0.0449),	the	Fh1βKO	FHcyt	1322	
(p=0.0391),	the	FHcyt	1322	(p=0.0025)	and	the	1322	mice	(p=0.0025)	(Figure	4.4.A,	Table	
4.5).	 The	 gut	 length	 of	 the	 Fh1βKO	 1322	 mice	 and	 the	 FHcyt	 or	 WT	 mice	 was	 not	
significantly	different	to	any	other	genotype.		




5cm	 shorter	 than	 the	 Fh1βKO	 mice,	 but	 this	 did	 not	 reach	 significance.	 Similarly,	 the	
length	of	the	LB	of	Fh1βKO	mice	was	at	least	1cm	longer	than	all	other	genotypes,	but	this	
was	not	significant.		






























Genotype	 Number	 Total		 SB		 LB		
WT	 5	 40.3±1.3	 33.3±1.2	 7.0±0.3	
1322	 12	 38.2±0.8	 31.3±0.7	 6.9±0.2	
FHcyt	 3	 39.2±1.5	 32.5±1.3	 6.7±0.4	
FHcyt	1322	 16	 38.4±0.6	 31.7±0.5	 6.7±0.2	
Fh1βKO	FHcyt	 3	 38.3±0.4	 31.5±0.8	 6.8±1.2	
Fh1βKO	FHcyt	1322	 7	 39.4±0.9	 32.5±0.5	 6.9±0.5	
Fh1βKO	 3	 46.0±0.8	 37.8±1.0	 8.2±0.4	
































































Figure	 4.9.	 Percentage	 of	 paneth	 cells	 in	 crypt	 of	 the	 small	 bowel.	 Gut	 tissue	 was	
embedded	 in	paraffin	and	 IHC	was	performed	 for	anti-lysozyme	which	 is	a	paneth	cell	
marker.	Stained	sections	were	scanned	using	a	Nanozoomer	Digital	Pathology	system	to	
create	high	quality	 images	which	were	used	to	calculate	percentage	positive	cells	 (n=3	









	 Epithelial	cells	(no.)	 Goblet	cells	(%)	 Paneth	 cells	
(%)	
Genotype	 Crypt		 Villi		 Crypt		 Villi		 Crypt	
WT	 50.5±6.7	 119.2±7.2	 31.0±3.8	 9.6±1.4	 26.2±4.1	
1322	 48.6±2.6	 114.9±2.7	 31.1±2.2	 12.3±1.6	 20.7±3.9	
FHcyt	 42.6±3.9	 114.5±2.7	 28.2±0.8	 8.1±0.3	 23.7±0.0	
FHcyt	1322	 51.0±4.9	 123.4±7.4	 31.4±2.4	 10.1±0.7	 21.3±2.9	
Fh1βKO	FHcyt	 43.1±2.4	 111.7±4.1	 28.3±0.8	 9.2±1.1	 25.2±1.2	
Fh1βKO	FHcyt	
1322	
49.5±2.6	 119.7±12.4	 31.8±1.5	 10.6±0.8	 15.1±0.3	
Fh1βKO	 51.6±4.3	 131.7±1.1	 27.2±3.4	 9.7±1.2	 23.7±2.7	
Fh1βKO	
1322	















counts	 which	 were	 much	 lower	 than	 FHcyt	 1322	 and	 1322.	 However,	 these	 were	 not	















highest	percentage	of	 total	polyps	 in	 the	SB2	section	compared	 to	Fh1βKO	1322,	FHcyt	










Figure	 4.10.	 Polyp	 count	 by	 intestinal	 site.	 Guts	 were	 removed,	 fixed,	 stained	 with	
methylene	blue	and	polyps	were	counted	using	a	dissection	microscope.	Total	polyp	count	
(±	SEM	(Table	4.7))	by	(A)	genotype,	(B)	by	site,	(C)	percentage	polyps	by	site.	Two-way	

















Genotype	 Total		 SB1		 SB2		 SB3	 LB		
1322	 30.58±5.32	 12.25±2.52	 9.67±1.90	 5.25±1.33	 3.42±0.94	
FHcyt	1322	 34.06±3.96	 16.44±1.66	 9.11±1.49	 5.94±1.28	 2.56±0.89	
Fh1βKO	
FHcyt	1322	
20.63±4.24	 10.50±2.08	 4.88±1.46	 2.88±1.16	 2.38±0.82	
Fh1βKO	
1322	
20.60±1.45	 9.40±1.10	 5.70±0.99	 3.90±0.74	 1.60±0.56	
	 Percentage	
Genotype	 	 SB1	 SB2	 SB3	 LB	
1322	 	 38.69±4.15	 31.88±2.73	 17.31±3.48	 12.14±3.67	










































Fh1βKO	 1322	 and	 Fh1βKO	 FHcyt	 1322	 mice	 (p=0.0424,	 two-way	 ANOVA)	 (Table	 4.9,	
A.4.10,11).	
Overall,	 of	 the	 high	 polyp	 count	 genotypes,	 FHcyt	 1322	 mice	 had	more	 >3mm	 polyps,	
whereas	1322	mice	had	more	<1-2mm	polyps.	The	polyp	burden	of	the	FHcyt	1322	mice	















Fh1βKO	 FHcyt	 1322,	 n=8,	 Fh1βKO	 1322	 n=10.	 Two-way	 ANOVA	 was	 performed,	 with	









Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 2.50±0.54	 4.48±1.29	 3.83±1.20	 1.83±0.59	
FHcyt	1322	 2.72±0.58	 3.78±0.56	 3.78±0.72	 6.17±0.82	
Fh1βKO	FHcyt	1322	 1.38±0.71	 2.63±0.56	 3.88±1.25	 2.63±0.78	
Fh1βKO	1322	 2.90±0.50	 2.20±0.53	 2.30±0.90	 2.00±0.61	
	 SB2	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 3.67±1.39	 3.33±0.87	 1.75±0.49	 1.78±0.51	
FHcyt	1322	 1.94±0.66	 2.78±0.62	 2.40±0.57	 1.78±0.49	
Fh1βKO	FHcyt	1322	 1.25±0.45	 1.00±0.57	 1.25±2.61	 1.38±0.65	
Fh1βKO	1322	 1.40±0.40	 1.60±0.27	 1.80±0.47	 0.90±0.46	
	 SB3	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 1.67±0.74	 2.67±0.89	 0.75±0.25	 0.17±0.11	
FHcyt	1322	 1.61±0.59	 2.00±0.64	 1.72±0.43	 0.61±0.28	
Fh1βKO	FHcyt	1322	 1.13±0.48	 0.38±0.38	 1.00±0.46	 0.38±0.26	
Fh1βKO	1322	 0.60±0.50	 1.20±0.42	 2.00±0.63	 0.10±0.10	
	 LB	
Genotype	 <1mm		 1-2mm		 2-3mm		 3+mm		
1322	 0.50±0.42	 1.00±0.39	 1.59±0.68	 0.33±0.26	
FHcyt	1322	 0.67±0.34	 1.33±0.46	 0.22±0.15	 0.33±0.23	
Fh1βKO	FHcyt	1322	 0.50±0.50	 1.25±0.73	 0.63±0.50	 0.00±0.00	















for	 polyp	 growth	 compared	 to	 all	 other	 genotypes.	 Nevertheless,	 the	 polyp	 size	 data	
suggests	that	elevated	blood	glucose	alone,	is	not	sufficient	to	generate	the	largest	polyps	
in	this	model.	Interestingly,	the	presence	of	the	FHcyt	allele	also	leads	to	a	slight	reduction	
in	 [glucose]	 found	 in	 the	 tissue,	 further	 alluding	 to	 the	 role	 of	 glucose	 and	 therefore	
fumarate	in	polyposis	in	this	model.		
Presence	 of	 FH	 in	 the	 β-cells	 of	 the	 pancreas	 allows	 insulin	 secretion	 and	 glucose	
homeostasis268,	as	discussed	 in	Chapter	1,	Section	1.12.	As	seen	previously,	addition	of	






































However,	 this	 is	not	backed	up	results	 from	Fh1βKO	FHcyt	1322	mice,	who	had	a	much	
lower	polyp	count	than	FHcyt	1322	mice,	and	a	similar	number	of	>3mm	polyps	to	1322	









This	 data	 suggests	 a	 role	 for	 cytoplasmic	 FH	 in	 tumourigenesis.	 This	 is	 in	 conflict	 to	
previous	in	vivo	studies	which	have	shown	that	overexpression	of	cytoplasmic	FH	in	renal	













are	 a	 number	 of	 questions	 that	 still	 need	 answering,	 such	 as,	 does	 FH	 contribute	 to	
tumorigenesis	in	CRC?	What	is	the	role	of	fumarate	and	succination	in	CRC?		
FH	 is	 the	 enzyme	 which	 breaks	 down	 fumarate	 into	 malate	 in	 the	 TCA	 cycle.	 It	 has	
previously	been	shown	that	 lack	of	FH	and	subsequent	 increase	 in	 [fumarate]	 leads	 to	
decreased	mitochondrial	respiration,	alteration	of	the	TCA	cycle	functionality	and	reversal	




In	 vivo,	CRC	can	be	extremely	nutrient	poor	and	oxygen	 low	at	 the	 tumour	 core335,407.	
Therefore,	 it	 is	 important	 to	 understand	 the	 molecular	 events	 involved	 in	 tumour	
adaptation	to	these	conditions;	the	effect	of	different	glucose	concentrations	on	CRC	cells	
in	hypoxia	requires	investigation.	Most	in	vitro	studies	use	oxygen	tensions	in	the	region	








inadequate	 vascularisation,	 in	 vitro	 CRC	 cells	 were	 cultured	 in	 different	 glucose	
concentrations	and	held	 in	0.2%	O2	 to	 simulate	hypoxia.	 To	aid	 investigations	 into	 the	












deficient	 mice	 and	 media	 from	 FH-deficient	 cell	 lines	 excrete	 increased	 amounts	 of	
fumarate	and	arginosuccinate	compared	to	their	WT	counterparts321.	This	was	found	to	
be	 a	 result	 of	 the	 reversed	 activity	 of	 the	 urea	 cycle	 enzyme	 arginosucinnate	 lyase	



















• Mitochondria	 concentration	 will	 be	 highest	 in	 CRC	 cells	 held	 in	 normoxia	
compared	to	hypoxia	and	cultured	in	no	glucose	compared	to	glucose.		






















(Figure	5.1;	Table	5.1.).	From	now	on	 [fumarate]	will	be	used	 to	denote	 ‘the	 fumarate	
concentration’.		
In	 DLD1	 cells	 [fumarate]	 was	 significantly	 higher	 at	 0.2%	 O2	 compared	 to	 20.9%	 O2	
(p=0.0011,	 one-way	 ordinary	 ANOVA;	 4.5-fold	 increase)	 (Figure	 5.1;	 Table	 A.5.1,2).	
[Fumarate]	was	also	higher	at	1%	O2	compared	to	20.9%	O2	but	the	difference	was	not	
significant	 (p=0.0897,	 one-way	 ordinary	 ANOVA;	 2.4-fold	 increase).	 The	 increase	 in	
[fumarate]	 between	 1%	 O2	 and	 0.2%	 O2	 was	 significant	 (p=0.0138,	 one-way	 ordinary	
ANOVA;	1.9-fold	increase).		
The	 HT55	 cell	 line	 followed	 the	 same	 pattern	 to	 the	 DLD1	 cell	 line.	 [Fumarate]	 was	
significantly	 higher	 at	 0.2%	 O2	 compared	 to	 20.9%	 O2	 (p<0.0001,	 one-way	 ordinary	






(p=0.0036,	 one-way	 ordinary	 ANOVA;	 2.3-fold	 decrease)	 (Figure	 5.1;	 Table	 A.5.1,2).	
[Fumarate]	was	also	significantly	decreased	at	1%	O2		compared	to	20.9%	(p=0.0035,	one-
way	 ordinary	 ANOVA;	 2.4-fold	 decrease).	 Furthermore,	 there	 was	 minimal	 difference	
between	[fumarate]	at	1%	and	0.2%	O2.	

































































occur	 in	 both	 tumours	 and	 spheroid	 models;	 such	 low	 oxygen	 tension	 remains	
significantly	understudied409–412,414.	Moreover,	there	were	differences	in	[fumarate]	in	CRC	
cells	recorded	by	mass	spectrometry	at	0.2%	O2	and	these	observations	warrant	further	






of	 glucose	 (further	 described	 in	 section	 5.2).	 However,	 another	 feature	 of	 T2D	 is	
hyperinsulinemia	which	was	not	modelled	in	this	work.	Therefore,	the	findings	must	be	
considered	in	light	of	this.		













Glutamate	 is	 another	 nutrient	 found	 in	 excess	 concentration	 in	 cell	 culture	 media.	
Glutamate	can	be	used	to	generate	energy	by	a	cell	through	the	TCA	cycle	by	entry	via	α-
ketoglutarate	(Chapter	1,	Figure	1.8).	Glutamine	is	the	preferred	anaplerotic	precursor	of	

















5.4	Doubling	 time	of	DLD1,	HT55	and	 SW837	 cells	 grown	 increased	as	 [glucose]	was	
reduced	in	their	media		
It	 is	 generally	 accepted	 that	 doubling	 time	 is	 a	 simple	 and	 quick	 health	 check	 of	 cell	
populations.	I	measured	the	doubling	time	of	cells	to	determine	stability	at	each	reduction	













one-way	 ANOVA)	 (Figure	 5.2.C)	 (Table	 A.5.3).	 There	 was	 a	 significant	 increase	 in	 the	
doubling	 time	 of	 cells	 grown	 in	 0mM	 compared	 to	 those	 grown	 in	 5mM	 and	 25mM	








doubling	 time	two-fold	 in	WT	Fh1	MEFs	compared	to	KO	Fh1	MEFs.	This	suggests	 that	




























































and	 SW837	 cell	 lines	 cultured	 with	 25mM,	 5mM	 and	 0mM	 glucose	 held	 in	 0.2%	 O2	




















in	25mM	glucose,	 the	viability	significantly	decreased	as	 [glucose]	 in	media	decreased.	
There	was	also	a	significant	effect	of	oxygen	on	the	viability	of	DLD1	cells	(p<0.0001)	and	














significant	 decrease	 in	 viability	 when	 SW837	 cells	 were	 cultured	 in	 0mM	 glucose	 and	



















































Preliminary	 [fumarate]	 data	 identified	 by	 mass	 spectrometry	 (Figure	 5.1)	 was	 only	
completed	on	CRC	cells	grown	in	25mM	glucose.	It	was	necessary	to	identify	the	effect	on	
[fumarate]	of	growing	CRC	cells	cultured	in	25mM,	5mM	and	0mM	glucose	at	20.9%	or	
0.2%	O2	 for	48	hours.	To	keep	costs	 low	for	 this	work,	 [fumarate]	of	 the	CRC	cell	 lines	







ANOVA;	Figure	5.5.A)	 (Table	A.5.7,8).	 [Fumarate]	 in	DLD1	cells	maintained	at	20.9%	O2	
increased	when	cells	were	cultured	with	5mM	glucose	compared	to	cells	cultured	with	
25mM	and	0mM	glucose.	When	DLD1	cells	were	held	in	0.2%	O2,	compared	to	DLD1	cells	
cultured	 in	 25mM	 glucose,	 [fumarate]	 significantly	 decreased	 as	 [glucose]	 in	 media	




in	 5mM	 or	 0mM	 glucose	 at	 20.9%	 O2	 compared	 to	 0.2%	 O2.	 A	 significant	 interaction	
















glucose,	 showed	 a	 significant	 decrease	 in	 [fumarate]	 as	 [glucose]	 in	media	 decreased	
(p<0.0001	with	two-way	ANOVA).	There	was,	therefore,	a	significant	effect	of	oxygen	on	
[fumarate]	 in	SW837	cells	 (p=0.0010)	 (Figure	5.5.C).	At	0mM	glucose,	 there	was	also	a	
significant	increase	in	[fumarate]	between	SW837	cells	cultured	at	0.2%	O2	compared	to	
20.9%	O2	(p<0.05).	However,	there	was	no	difference	in	[fumarate]	between	SW837	cells	
cultured	 in	 25mM	 or	 5mM	 glucose	 at	 20.9%	 O2	 compared	 to	 0.2%	 O2.	 A	 significant	




showed	a	slightly	different	pattern	 to	DLD1	and	HT55	cells.	The	main	difference	 is	 the	
















is	 a	 much	 more	 sensitive	 method	 compared	 to	 the	 fluorometric	 assay.	 Using	 mass	
spectrometry,	the	ratio	of	fumarate	between	DLD1,	HT55	and	SW837	cells	treated	with	
0.2%	O2	compared	to	20.9%	O2	is	4.58,	6.75	and	0.43	respectively.	Whereas,	when	using	
the	 fluorometric	 assay,	 the	 ratio	 of	 fumarate	 between	 DLD1,	 HT55	 and	 SW837	 cells	
treated	with	 0.2%	O2	 compared	 to	 20.9%	O2	 is	 3.3,	 2.56	 and	 1.23	 respectively.	 These	























































South	 Carolina)	 create	 an	 antibody,	 which	 was	 made	 available	 to	 me,	 that	 detects	
succination	(2-SC	motifs).	An	equal	amount	of	protein	was	loaded	per	cell	line	according	
to	a	protein	quantification	assay.	
However,	 this	 does	 not	 provide	 an	 adequate	 means	 of	 quantifying	 the	 levels	 of	

















hours.	 An	 equal	 amount	 of	 protein	 was	 loaded	 per	 sample	 according	 to	 a	 protein	














48	 hours,	 the	 cells	 were	 then	 harvested	 and	 assayed	 (Chapter	 2,	 Section	 2.3.6).	 The	
experiment	was	done	three	times	for	each	condition.	
There	was	a	significant	effect	of	[glucose]	on	the	activity	of	FH	in	DLD1	cells	(p=0.0007,	

















was	 no	 significant	 difference	 between	 the	 different	 glucose	 concentrations,	 although	
there	was	a	small	drop	in	activity	in	SW837	cells	cultured	in	0mM	glucose.	A	significant	
effect	of	oxygen	on	SW837	FH	activity	 in	SW837	cells	was	identified	(p=0.0297)	(Figure	









MEFs	 and	 KO	 Fh1	 MEFs.	 There	 was	 not	 a	 significant	 effect	 of	 O2	 (p=0.2980)	 or	 the	
interaction	of	cell	line	and	oxygen	(p=0.1983)	on	the	activity	of	FH	in	MEFs	(Figure	5.7.C).	
This	work	 identifies	that	FH	 is	active	 in	the	CRC	cell	 lines	used	 in	this	study.	There	are,	
however,	differences	between	the	cell	lines.	DLD1	cells	held	in	20.9%	O2	and	cultured	with	
25mM	or	5mM	glucose	in	their	media	have	a	much	higher	FH	activity	when	compared	to	
their	 SW837	 counterparts.	 SW837	 cells	 are	 not	 as	 flexible	 with	 their	 FH	 activity.	



































To	 further	quantify	 the	effect	of	different	 [glucose]	 in	cell	 culture	media	on	FH,	 it	was	
necessary	to	quantify	the	amount	of	FH.	Cells	were	held	in	20.9%	or	0.2%	O2	for	48	hours,	
then	 fixed	 and	 stained	with	 DAPI,	 plasma	membrane	 stain	 and	 an	 antibody	 validated	










FH	 foci	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	 increased	






















20.9%	 O2	 compared	 to	 0.2%	 O2.	 In	 line	 with	 these	 findings,	 a	 significant	 interaction	
between	[glucose]	and	oxygen	tension	on	the	area	of	FH	per	cell	 in	DLD1	cells	was	not	
identified	(p=0.	0.6619).	
[Glucose]	 had	 a	 significant	 effect	 on	 the	 number	 of	 FH	 foci	 per	 cell	 in	 SW837	 cells	
(p<0.0001)	 (Figure	 5.9.C)	 (Table	 A.5.11,12).	When	 SW837	 cells	 were	 at	 20.9%	O2,	 the	
number	 of	 FH	 foci	 per	 cell	 in	 SW837	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	































cells	 treated	with	0.2%	O2	have	1.97	 fold	more	FH	area	 compared	 to	 cell	 treated	with	
20.9%	O2.		
This	data	suggests	that	hypoxia	does	not	influence	FH	production	dramatically.	There	are	
minimal	 non-significant	 differences	 between	 cells	 held	 in	 20.9%	 and	 0.2%	 O2	 in	 all	
[glucose].	There	was	a	2-fold	increase	in	amount	of	area	of	FH	protein	in	cells	cultured	
with	 0mM	glucose,	 compared	 to	 cells	 cultured	with	 25mM	and	 5mM	glucose	 at	 both	
20.9%	and	0.2%	O2.	However,	there	was	at	least	a	2-fold	decrease	in	FH	activity	in	cells	
cultured	with	0mM	glucose	 compared	 to	 cells	 cultured	 in	 25mM	and	5mM	glucose	 at	
20.9%	O2.	The	FH	activity	in	DLD1	cells	was	not	different	at	0.2%	O2.	This	suggests	that	at	
0mM	 glucose	 FH	 is	 abundant	 but	 not	 active.	 This	 may	 be	 due	 to	 a	 lack	 of	 substrate	





Figure	5.8.	 Fumarate	hydratase	 staining	analysis	process.	Cells	were	held	 in	20.9%	or	
0.2%	O2	for	48	hours,	then	fixed	and	stained	with	DAPI,	cell	mask	and	FH	antibody.	The	
staining	was	imaged	using	an	InCell	2200	microscope.	And	the	images	were	then	analysed	










Figure	 5.9.	 Fumarate	 hydratase	 foci	 and	 area	 per	 cell.	 DLD1	 and	 SW837	 cells	 were	




































Unfortunately,	 it	was	difficult	 to	 identify	a	housekeeping	gene	which	was	stable	 for	all	
three	cell	lines	under	the	changes	in	glucose	and	oxygen	tension	used	(Figure	5.10).	It	was	
decided	to	select	different	housekeeping	genes	for	each	CRC	cell	line:	DLD1	results	were	
normalised	 to	a	geomean	of	18S	and	RPLPO;	HT55	 to	actin;	 SW837	 to	B2M.	Data	was	
analysed	by	the	½^ct	method373.	
Normalised	 RT-PCR	 data	 of	 the	 19	 genes	 across	 the	 three	 cell	 lines	 was	 subjected	 to	
multivariate	analysis	 to	uncover	 the	relationship	between	the	expression	of	each	gene	
and	 the	 [glucose]	 and	 oxygen	 tension	 conditions	 that	 the	 cells	 were	 held	 in.	 A	 linear	
regression	model	was	used	to	determine	a	p-value	for	each	gene	in	relation	to	[glucose],	
oxygen	 tension	 and	 interaction	 of	 [glucose]	 and	 oxygen	 tension.	 The	 19	 genes	 were	
ranked	 according	 to	 the	 p-value	 for	 [glucose].	 Next	 the	 normalised	 RT-PCR	 data	 was	
expressed	as	fold	change	from	cells	cultured	in	25mM	glucose	at	20.9%	O2.	This	data	is	
shown	in	Figure	5.11	as	a	heat	map.		
The	 p-values	 for	 oxygen	 tension	 and	 interaction	 of	 [glucose]	 and	 oxygen	 tension	 are	


























Catalyses	 the	 conversion	 of	 pyruvate	 to	 lactate.	
Transcriptionally	 regulated	 by	 HIF-1α.	 Elevated	 in	 many	
cancers	and	linked	to	tumour	growth	and	invasion428.		
HK2	 Hexokinase	2	 Catalyses	the	first	step	of	glucose	metabolism	(glucose	to	
glucose	 6-phosphate).	 Upregulated	 in	 many	 tumours.	



























Enzyme	 that	 catalyses	 the	 conversion	 of	 fumarate	 to	
















	The	 terminal	 enzyme	 of	 the	 mitochondrial	 respiratory	












A	 transcription	 factor	 that	 has	 a	 major	 role	 in	 tumour	
response	to	hypoxia407.	Leads	to	upregulation	of	glycolysis	





Also	 known	 as	 aryl	 hydrocarbon	 receptor	 nuclear	



























































significantly	 altered	 the	 expression	 of	 BAX	 (p=0.01370),	 CA9	 (p=0.01723),	 PDK1	
(p=0.01900)	 and	 LDHA	 (p=0.02906).	 The	 oxygen	 tension	 significantly	 altered	 the	
expression	of	CA9	(p=0.00958),	PDK1	(p=0.00864),	LDHA	(p=0.00836),	HK2	(p=0.00221),	
HIF-2α	(p=0.03318)	and	GLUT1	(p=0.00125).	When	oxygen	tension	and	[glucose]	are	both	





[glucose]	 is	 lowered.	 This	 suggests	 that	 apoptosis	 is	 triggered	 less	via	mitochondria	 in	








CA9	 and	 HIF-2α are	 involved	 in	 the	 cells	 response	 to	 hypoxia	 suggesting	 there	 is	 a	
relationship	between	hypoxia	and	[glucose],	as	already	widely	reported	in	literature444,445.	
PDK1,	 LDHA,	 HK2	 and	 GLUT-1	 are	 all	 involved	 in	 glycolysis	 (Chapter	 1,	 Figure	 1.7),	














Figure	 5.11.	Altered	 CRC	 cell	 gene	 expression	 profile	 after	 48	 hours	 treatment	 with	
20.9%	or	0.2%	oxygen.	A	heat	map	of	log	transformed	fold	changes	between	the	different	
oxygen	tensions	normalised	to	25mM	and	20.9%	treatment	is	shown.	Genes	are	ranked	








FH	 protein	 can	 be	 found	 throughout	 the	 cell,	 however,	 it	 is	 mainly	 found	 within	 the	
mitochondria	 where	 it	 participates	 in	 the	 TCA	 cycle.	 To	 understand	 if	 changes	 in	 the	













cells	 (p<0.0001)	 (Figure	 5.13.A).	 When	 DLD1	 cells	 were	 at	 20.9%	 O2,	 the	 number	 of	
mitochondrial	 foci	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	 significantly	
increased	compared	to	DLD1	cells	cultured	in	25mM	glucose	(p<0.0001)	as	well	as	DLD1	
cells	cultured	in	5mM	glucose	(p<0.0001).	When	DLD1	cells	maintained	at	0.2%	O2,	the	
number	 of	 mitochondrial	 foci	 per	 cell	 in	 DLD1	 cells	 cultured	 in	 0mM	 glucose	 was	
significantly	 increased	compared	 to	DLD1	cells	 cultured	 in	25mM	glucose	 (p<0.01)	and	
increased	 compared	 to	 DLD1	 cells	 cultured	 in	 5mM	 glucose.	 Oxygen	 had	 a	 significant	
effect	 on	 the	 number	 of	 mitochondrial	 foci	 per	 cell	 in	 DLD1	 cells	 (p=0.0140)	 (Figure	
5.13.A).	 There	was	 a	 significant	 increase	 in	 the	 number	 of	mitochondrial	 foci	 per	 cell	






[Glucose]	 had	 a	 significant	 effect	 on	 the	 area	 of	 mitochondria	 per	 cell	 in	 DLD1	 cells	
(p<0.0001)	 (Figure	 5.13.B).	 When	 DLD1	 cells	 were	 held	 at	 20.9%	 O2,	 the	 area	 of	
mitochondria	per	cell	in	DLD1	cells	cultured	in	0mM	glucose	was	significantly	increased	
compared	 to	 DLD1	 cells	 cultured	 in	 25mM	 glucose	 (p<0.0001)	 as	 well	 as	 DLD1	 cells	
cultured	 in	 5mM	 glucose	 (p<0.0001).	 When	 DLD1	 cells	 were	 at	 0.2%	 O2,	 the	 area	 of	
mitochondria	per	cell	in	DLD1	cells	cultured	in	0mM	glucose	was	significantly	increased	
compared	to	DLD1	cells	cultured	in	25mM	glucose	(p<0.05)	as	well	as	DLD1	cells	cultured	
in	 5mM	 glucose	 (p<0.01).	 There	 was	 no	 significant	 effect	 of	 oxygen	 on	 the	 area	 of	








cells	 (p=0.0003)	 (Figure	 5.13.C).	When	 SW837	 cells	were	maintained	 at	 20.9%	O2,	 the	
number	 of	 mitochondrial	 foci	 per	 cell	 in	 SW837	 cells	 cultured	 in	 0mM	 glucose	 was	
increased	 compared	 to	 SW837	 cells	 cultured	 in	 25mM	glucose	 as	well	 as	 SW837	 cells	
cultured	in	5mM	glucose.	When	SW837	cells	at	0.2%	O2,	the	number	of	mitochondrial	foci	
per	cell	in	SW837	cells	cultured	in	0mM	glucose	was	increased	compared	to	SW837	cells	
cultured	 in	 25mM	 glucose	 and	 was	 significantly	 increased	 compared	 to	 SW837	 cells	
cultured	in	5mM	glucose	(p<0.001).	Oxygen	had	a	significant	effect	of	on	the	number	of	
mitochondrial	 foci	 per	 cell	 in	 SW837	 cells	 (p=0.9646)	 (Figure	 5.13.C).	 There	 was	 a	 no	
difference	in	the	number	of	mitochondrial	foci	per	cell	between	SW837	cells	cultured	in	




[Glucose]	 had	 a	 significant	 effect	 on	 the	 area	 of	mitochondria	 per	 cell	 in	 SW837	 cells	
(p<0.0001)	(Figure	5.13.D).	When	SW837	cells	were	maintained	at	20.9%	O2,	the	area	of	
mitochondria	 per	 cell	 in	 SW837	 cells	 cultured	 in	 0mM	 glucose	 was	 not	 significantly	
different	compared	to	SW837	cells	cultured	in	25mM	glucose	or	in	5mM	glucose.	When	










DLD1	 cells	 were	 cultured	 in	 0mM	 glucose	 their	 mitochondrial	 foci	 number	 and	 area	
increase,	more	so	when	held	at	20.9%	O2	compared	to	0.2%	O2.	When	SW837	cells	were	

































































to	 identify	 FH	 staining	which	was	 present	 in	 the	 same	 area	 as	mitochondrial	 staining	
(Figure	15,	Table	5.12).	The	remaining	FH	staining	was	then	classified	as	cytoplasmic	or	






























Figure	 5.15.	 Distribution	 of	 FH	 within	 CRC	 cells.	 (A)	 DLD1	 and	 (B)	 SW837	 cells	 were	

























As	 it	 has	 been	 found	 previously	 that	 there	 was	 more	 mitochondrial	 staining	 in	 cells	
cultured	in	0mM	glucose	compared	to	25mM	and	5mM	glucose	(Chapter	5,	Section	5.9),	
the	 next	 step	 was	 to	 determine	 if	 these	 mitochondria	 were	 functional.	 A	 functional	
mitochondrion	will	provide	energy	to	the	cell	via	the	TCA	cycle,	which	involves	fumarate	
and	FH.		
To	 determine	 differences	 in	mitochondrion	 function	 the	 Seahorse	 XF	 Cell	Mito	 Stress	




cells.	 The	 compounds	 oligomycin,	 carbonyl	 cyanide-4	 (trifluoromethoxy)	
phenylhydrazone	(FCCP),	rotenone	and	antimycin	A	(described	in	Table	5.5)	are	serially	
injected	to	measure	ATP	production,	maximal	respiration,	non-mitochondrial	respiration,	























Disrupts	 the	 mitochondrial	 membrane	
potential.	An	uncoupling	agent	that	collapses	
the	 proton	 gradient	 resulting	 in	 an	
uninhibited	 flow	 of	 electrons	 through	 the	














ATP	production	 ATP	 produced	 by	 the	 mitochondria.	 The	 decrease	 in	 OCR	 upon	
oligomycin	 administration	 represents	 the	 proportion	 of	 basal	
respiration	that	was	being	used	for	ATP	production.		
Proton	leak	 Basal	respiration	which	is	not	coupled	to	ATP	production.	Can	be	a	























mitochondrial	 function	 by	 directly	measuring	 the	 oxygen	 consumption	 rate	 of	 cells.	
Sequential	injections	of	oligomycin,	FCCP,	and	a	mix	of	rotenone	and	antimycin	A	enable	
measurement	of	ATP	production,	maximal	respiration	and	non-mitochondrial	respiration.	






the	media	 in	 which	 the	 cells	 were	 cultured,	 the	 higher	 the	 OCR	measurement	 of	 the	
mitochondrial	 metabolic	 parameter.	 DLD1	 cells	 had	 lower	 OCR	 measurements	 of	 all	










0mM	 glucose.	 This	 suggests	 that	 the	 cells	 are	 still	 flexible	 in	 their	 energy	 creating	
pathways.	
Overall	 it	 was	 found	 that	 cells	 cultured	 with	 0mM	 glucose	 have	 the	 highest	 basal	
mitochondrial	respiration	rate,	produce	the	most	ATP	via	mitochondria,	have	the	highest	
maximal	capacity	in	their	mitochondria	as	well	as	the	greatest	spare	capacity.	When	cells	
cultured	 in	 0mM	 glucose	 are	 treated	 with	 25mM	 glucose	 for	 one	 hour,	 all	 of	 these	
measurements	are	reduced	and	significance	is	lost	when	compared	to	5mM	and	25mM	
glucose	cells.	They	have	potentially	upregulated	glycolysis	within	1	hour.		
KO	 Fh1	MEFs	 have	 reduced	mitochondrial	 function	 compared	 to	WT	 Fh1	MEFs	 on	 all	
parameters	confirming	that	FH	has	a	critical	role	in	mitochondrial	metabolism.	It	can	be	
concluded	 from	 this	 data	 that	 glucose	 presence	 prevents	 cells	 from	 using	 their	
mitochondria	to	full	capacity.		
Measuring	other	mitochondrial	parameters	such	as	membrane	permeability,	fusion	and	






the	 mitochondrial	 metabolism	 of	 (A)	 DLD1	 cells	 in	 media	 at	 their	 denoted	 glucose	
concentration,	(B)	DLD1	cells	all	treated	with	25mM	glucose	for	1	hour	prior	to	the	assay,	

















cells	 all	 treated	with	 25mM	 glucose	 for	 1	 hour	 prior	 to	 the	 assay,	 (E)	MEFs	 in	 25mM	











































































































































































































with	 25mM	 glucose	 cells	 are	 grouped	 together	 suggesting	 that	 their	 glycolysis	 and	
























which	 are	 as	 a	 result	 of	 differences	 in	 vasculature.	 Solid	 tumours,	 such	 as	 CRC,	 have	
deficient	vascular	systems	due	to	excessive	and	unregulated	cancer	cell	growth	alongside	
insufficient	 angiogenesis.	 As	 a	 result,	 perfusion	 within	 solid	 tumours	 is	 inadequate,	
leading	to	tumour	regions	which	are	transiently	and	chronically	exposed	to	nutrient	and	
oxygen	 starvation448.	 Cancer	 cells	 respond	 to	 these	 conditions	 by	 adapting	 their	
metabolism	 to	 enable	 survival	 and	 proliferation.	 Several	 reports	 have	 indicated	 that	





glucose	 consumption	and	 lactate	production	 in	 cancer	 cells,	 despite	 low	availability	of	
oxygen	for	complete	oxidation	of	glucose,	known	as	the	Warburg	effect446.		
The	 interruption	of	 glycolysis	by	 inhibition	of	GLUT-1,	HK2	and	LDH	 for	example,	 is	 an	
attractive	method	for	cancer	treatment454–456.	However,	targeting	glycolysis	has	not	yet	
translated	 into	 the	 clinic.	 The	 precise	 effects	 of	 oncogenes	 and	 mutations	 in	 tumour	
suppressor	genes	on	CRC	cell	metabolism	are	 still	disputed.	Tumours	are	known	to	be	
heterogeneous	so,	it	is	likely	that	cancer	cells	in	different	tumour	regions	have	different	
adaptions	 according	 to	 their	 microenvironment	 pressures457.	 Cells	 further	 from	 blood	
vessels	 will	 have	 selection	 pressure	 for	 those	 that	 survive	 low	 oxygen	 and	 nutrient	
conditions.	 This	 heterogeneity	 contributes	 to	 therapy	 resistance	 and	 poses	 a	 major	
challenge	for	personalised	therapy.		
In	 vitro	 studies	 to	 determine	 effect	 of	 oxygen	 deprivation	 or	 hypoxia	 on	 cancer	 cells	
predominantly	 use	 oxygen	 concentrations	 below	 2%144.	 Healthy	 tissues	 experience	
between	2	and	9%	oxygen144.	Experimentally	such	oxygen	tensions	are	achieved	through	
use	of	a	heated	humidified	chamber	where	the	oxygen	concentration	can	be	controlled.	
Cells	 are	 plated	 in	 atmospheric	 oxygen	 (20.9%)	 and	 then	 transferred	 to	 the	 hypoxic	











clinic.	 And,	 in	 vitro	 studies	 to	 determine	 effect	 of	 glucose	 deprivation	 on	 cancer	 cells	
typically	remove	glucose	from	the	media	for	24-72	hours	and	then	test	for	observations.	
The	removal	of	glucose	from	the	media	in	this	short	time	frame	often	leads	to	cancer	cell	




I	 gradually	 reduced	 the	 concentration	of	 glucose	 in	 CRC	 cell	media	 over	 a	 period	of	 3	
months	instead	of	dropping	the	glucose	concentration	dramatically.	Over	this	prolonged	
time	period,	glucose	would	not	be	totally	removed	from	the	cells,	so	those	cultured	 in	
0mM	glucose	were	 truly	glucose	 free.	This	approach	has	not	been	 taken	before	 to	my	





baseline	 differences.	 As	 expected,	 reducing	 the	 glucose	 concentration	 increased	 the	
doubling	time	of	all	CRC	cell	lines	(Figure	5.1).	Glycolysis	is	a	major	producer	of	ATP	for	
the	cancer	cell,	 therefore,	 if	 less	glucose	 is	entering	the	pathway	then	 less	ATP	will	be	
made	 for	 processes	 like	 proliferation.	 However,	 there	 is	 more	 than	 one	 metabolic	
pathway	 that	 can	 generate	 ATP.	 It	 is	 known	 that	 glutamine	 is	 metabolised	 more	
abundantly	 than	 other	 non-essential	 amino	 acids	 in	 cancer	 cells461,462.	 Glutamine	
remained	in	the	CRC	cell	media	at	2mM	regardless	of	glucose	concentration.	This	allowed	
	 243	
for	 only	 the	 effects	 of	 changing	 glucose	 concentration	 to	 be	 studied.	 Glutamine	 is,	
therefore,	 likely	 to	be	contributing	to	cell	 survival	under	glucose	 free	conditions.	DLD1	
cells	have	previously	been	shown	to	have	increased	levels	of	glutamate	dehydrogenase	1	
(GLUD1)	which	metabolises	glutamine	and	feeds	it	into	the	TCA	cycle	via	α-ketoglutarate	
to	 generate	 ATP397.	 And	 knock-down	 of	 GLUT1	 in	 DLD1	 cells	 in	 glucose-deprived	
conditions	(removal	of	glucose	for	72	hours)	led	to	decreased	growth397.		
Doubling	time	of	KO	Fh1	MEFs	was	higher	than	WT	Fh1	MEFs	(Figure	5.2).	This	is	 likely	











pancreatic	 cancer	 cells463,	 human	 prostate	 cancer	 cells463,	 human	 pharyngeal	 cancer	








oxygen	 are	 in	 low	 supply	 and	 cell	 energy	 demand	 is	 high,	 cell	 survival	 can	 be	
compromised.	The	in	vitro	cell	viability	results	(Figure	5.5)	corroborate	this	observation:	






Next,	 it	was	 important	 to	understand	 the	changes	 in	 fumarate	and	how	they	 relate	 to	
[glucose]	 and	 oxygen	 tension.	 It	 has	 previously	 been	 shown	 that	 [fumarate]	 can	 be	
elevated	200-300	times	in	HLRCC	samples	compared	to	normal	fibroblast	cell	samples324.	
Stomach	 and	 colon	 cancer	 samples	 have	 also	 been	 shown	 to	 have	 elevated	 fumarate	
compared	 to	 normal	 tissue,	which	 is	 attributed	 the	 oncogenic	 changes	within	 the	 cell	
leading	to	increased	demand	for	ATP	leading	to	an	increase	in	metabolism	and,	therefore,	
more	 fumarate	 and	 other	metabolites335.	 Fumarate	 impairs	 HIF-1	 prolyl	 hydroxylation	





















effect	 of	 [glucose]	 on	 [fumarate]	was	more	 closely	 related	 to	 cell	 line.	 In	 SW837	 cells	
[fumarate]	was	highest	in	cells	cultured	with	25mM	glucose,	but	in	DLD1	and	HT55	cells,	





The	 same	 grouping	 of	 cell	 lines	 occurred	 in	 the	 [fumarate]	mass	 spectrometry	 results	
(Figure	5.1).	I	can	find	no	literature	which	suggests	that	cells	from	the	colon	and	rectum	
have	intrinsically	different	fumarate	or	glucose	levels.	However,	it	is	known	that	there	is	





























glucose	 and/or	 0.2%	 O2.	 This	 suggests	 that	 in	 the	 DLD1	 cell	 line,	 FH	 activity	 is	 more	
dependent	on	[glucose]	and	oxygen	availability	relative	to	the	SW837	cell	line	where	FH	
activity	 is	 only	 slightly	 increased	 at	 each	 glucose	 concentration	 when	 cells	 were	
maintained	in	20.9%	O2	over	0.2%	O2.	FH	activity	has	been	linked	to	cell	growth	rate	and	
carbon	 source	 utilisation	 independently	 by	 a	 study	 done	 in	 Escherichia	 coli470.	 The	
researchers	found	that	FH	activity	increased	under	aerobic	conditions	and	when	acetate	
was	 used	 instead	 of	 glucose	 as	 the	 sole	 carbon	 source.	 It	 has	 also	 been	 shown	 that	






background	value,	 and	 substituted	 from	all	 final	 readouts.	As	CRC	 cell	 lines	produce	a	
readout	from	this	assay,	this	suggests	that	FH	activity	is	not	fully	compromised	in	CRC	like	






























One	other	point	of	note	is	that	the	number	of	FH	foci	 in	DLD1	cells	 is	 lower	in	0.2%	O2	
compared	to	20.9%	O2,	however,	the	FH	area	is	similar.	This	could	suggest	that	the	hypoxic	











studies	 have	 been	 published	 that	 I	 can	 find.	 When	 multivariate	 linear	 regression	 is	











or	 inactivation	 is	 rare	 in	 cancers,	 but	 has	 been	 reported	 in	 CRC476.	 Interestingly,	 BAX	
protein	has	also	been	shown	to	be	prognostic	in	human	CRC,	with	higher	amounts	linked	
to	more	 severe	disease443.	 A	 paper	 studying	 the	 effect	 of	 loss	 of	BAX	 in	HCT116	 cells,	
suggests	that	loss	of	BAX	expression	leads	to	a	defect	in	mitochondrial	oxidative	capacity	
and	 favouring	 of	 the	 glycolysis	 pathway	 by	 the	 cell473.	 In	 my	 work,	 a	 reduction	 in	





CA9	 and	 HIF-2α are	 involved	 in	 the	 cells	 response	 to	 hypoxia	 suggesting	 there	 is	 a	
relationship	between	hypoxia	and	[glucose],	as	already	widely	reported	in	literature444,445.	
PDK1,	LDHA,	HK2	and	GLUT-1	are	all	 involved	 in	glycolysis,	suggesting	that	glycolysis	 is	


















of	 glucose,	mitochondria	 become	more	 fused479.	 This	 suggests	 that	 the	 larger	 area	 of	
mitochondria	 found	 in	 cells	 cultured	 in	 0mM	 glucose	 is	 due	 to	 mitochondrial	 fusion.	
However,	the	number	of	mitochondrial	foci	is	not	reduced	when	DLD1	and	SW837	cells	
are	cultured	in	0mM	glucose,	suggesting	there	is	a	similar	number	of	mitochondria	which	














were	 held	 in	 0.2%	O2,	which	 could	 be	 due	 to	 the	 participation	 of	 FH	 in	 DNA	 damage	
response	as	suggested	earlier.		
Fibroblast	 cell	 lines	 have	 previously	 been	 shown	 to	 have	 an	 equal	 or	 more	 balanced	
distribution	of	FH	between	mitochondria	and	cytoplasm	via	Western	blot314,	when	these	





















When	more	mitochondria	are	present,	 the	cell	has	a	greater	 spare	capacity.	 For	other	
measurements,	 there	 was	 no	 significant	 difference	 in	 DLD1	 cells.	 In	 SW837	 cells	 ATP	
production	and	maximal	respiration	is	significantly	higher	in	cells	cultured	in	0mM	glucose	
	 251	
compared	 to	 25mM	 glucose.	 Even	 though	 it	 is	 known	 that	 mitochondrial	 respiration	
generates	more	ATP	than	glycolysis	I	was	still	surprised	by	the	huge	difference	seen.	This	
may	again	be	due	to	the	increase	in	number	of	mitochondria	in	SW837	cells	cultured	with	
0mM	glucose.	 To	 confirm	 the	 change	 in	mitochondria	 area	 and	number,	 further	work	
measuring	mitochondrial	DNA	would	add	to	the	evidence	(Chapter	8,	Section	8.3).	
There	was	a	great	difference	between	OCR	for	DLD1	and	SW837	cells.	As	SW837	cells	had	






measured	 in	 this	 study.	 Perhaps	 DLD1	 cells	 are	 using	 an	 alternative	 form	 of	 energy	
generation.	SW837	cells	cultured	in	0mM	glucose	also	have	a	longer	doubling	time	than	









parameters.	 This	 suggests	 that	 these	 cells	 are	 not	 permanently	 changed	 from	 being	




These	 results	 are	 further	 highlighted	with	 the	metabolic	 phenotype	 plot.	 SW837	 cells	
cultured	 in	 0mM	 glucose	 are	 much	 more	 energetic	 than	 any	 other	 cell	 type	 tested.	
	 252	
Unfortunately,	the	Seahorse	Mito	Stress	Test	could	not	be	done	with	cells	held	in	0.2%	O2	
as	the	Seahorse	machine	 is	not	within	the	 INVIVO	chamber	 I	used	for	reducing	oxygen	




phenotype	 is	 linked	 to	 cancer	 progression	 and	 aggressiveness.	 There	 was	 not	 much	
difference	in	OCR	measured	by	Seahorse	of	cells	cultured	in	25mM	and	5mM	glucose	at	
20.9%	O2,	which	 suggests	 that	 cancer	cells	 can	generate	energy	well	 via	glycolysis	and	
mitochondrial	metabolism	with	a	wide	range	of	[glucose].	Nevertheless,	I	was	surprised	
to	 see	 SW837	 cells	 cultured	with	 0mM	 glucose	 generating	 such	 high	 OCR	 reads.	 This	
suggests	 that	 as	 expected	 tumour	 cells	 are	 able	 to	 adapt	 to	 different	 tumour	




as	the	Seahorse	machine	 is	not	within	the	 INVIVO	chamber	 I	used	for	reducing	oxygen	























This	 work	 is	 focused	 on	 examining	 DUOX	 expression	 in	 xenografts	 of	 DLD1	 cells	 in	
response	to	exposure	to	the	oxaliplatin	and	cetuximab.	The	motivation	for	this	work	was	
the	 surprising	 results	 from	 the	 New	 Eloxatin	 Peri-Operative	 Chemotherapy	 (EPOC)	










failure129–131.	 Newer	 biologic	 treatments,	 such	 as	 cetuximab,	 are	 being	 developed	 and	










5-FU	 chemotherapy	 in	 first-line	 treatment	 of	 advanced	 CRC,	 did	 not	 confirm	 the	





studies	 and	 used	 very	 similar	 investigational	 strategies	 to	 assess	 any	 improvement	 of	
patient	outcome	with	the	addition	of	cetuximab	to	oxaliplatin	and	5-FU	therapy132.		
Antagonism	between	platinum	drugs	and	cetuximab	has	been	reported	previously	in	KRAS	
wild-type	 CRCs497.	 ROS	 have	 been	 shown	 to	mediate	 resistance	 to	 chemotherapy.	 For	
example,	 preclinical	 studies	 have	 shown	 that	 treatment	 with	 platinum	 drugs	 and	
cetuximab	 in	 combination	 with	 gefitinib	 in	 colon	 and	 lung	 cancer	 cells	 resulted	 in	




ROS	 includes	 superoxide	and	hydrogen	peroxide.	 In	 the	 cell,	ROS	are	produced	by	 the	
membrane	 bound	 enzymatic	 family	 of	 NADPH	 oxidases	 (NOX	 1-5	 and	 dual	 oxidases	
DUOX1/2)500,	 the	 mitochondrial	 electron	 transport	 chain,	 xanthine	 oxidase	 as	 well	 as	
other	 systems501–503.	ROS	 formation	 can	 lead	 to	 tumour	 initiation	and	 /	or	progression	
(Chapter	1,	Section	1.8).	Therefore,	ROS	is	an	important	signalling	molecule	which	controls	
the	 balance	 between	 proliferation	 and	 anti-proliferative	 signalling	 pathways	 in	 vivo,	




The	work	 in	this	chapter	specifically	 involves	DUOX2	and	 its	obligate	maturation	factor	
DUOXA2	(Chapter	1,	Section	1.15).	In	summary,	DUOX2	was	initially	described	as	a	H2O2-
producing	 enzyme	 in	 the	 thyroid	 and	 does	 indeed	 have	 an	 important	 role	 in	 thyroid	




and	 used	DUOX2/DUOXA2	 qPCR	 and	 in	 situ	 hybridisation	 (ISH)	 to	 identify	 and	 locate	
mRNA	in	the	intestinal	mucosa	of	patients	with	UC	and	CRC139.	High	levels	of	DUOX2	have	
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• DUOX2	 and	 DUOXA2	 expression	 is	 increased	 with	 oxaliplatin	 treatment,	 and	
reduced	with	cetuximab	treatment.		







• Analyse	DUOX2	 and	DUOXA2	 gene	 expression	 by	 RT-PCR,	 and	 DUOX2	 protein	
expression	by	IHC.		











Daniel	Hochhauser’s	 lab	and	Bruce	Williams	at	 the	animal	unit.	At	 the	endpoint	of	 the	
study,	 I	 collected	 the	xenograft	 tissue,	 split	 the	 xenograft	 tissue	 into	 two	 sections	and	
fixed	one	piece	of	 tissue	with	neutral	buffered	 formalin,	which	was	 then	embedded	 in	
paraffin	wax	by	Rebecca	Carroll	from	the	pathology	service	at	The	Royal	London	Hospital.	
The	 second	 piece	 of	 tissue	 was	 submerged	 in	 Tissue	 Protect	 solution	 and	 then	 RNA	
extracted	from	these	samples.				
	
Proven	 techniques	were	 used	 to	 determine	 levels	 of	 DUOX2	mRNA	 in	 the	 embedded	




whereas	 combination	 with	 cetuximab	 greatly	 attenuated	 this	 response	 to	 5.3-fold	
(p=0.16)	 (Figure	 6.1A	 and	B).	 Analysis	 of	DUOXA2	mRNA	 revealed	 a	 similar	 pattern	 to	
DUOX2	results;	oxaliplatin	alone	significantly	upregulated	expression	of	DUOXA2	mRNA	
(p=0.02),	while	combination	with	cetuximab	only	increased	DUOXA2	mRNA	by	4.77-fold	




than	 treatment	 with	 cetuximab	 or	 treatment	 with	 a	 combination	 of	 oxaliplatin	 and	







determined	 by	 RT-PCR,	 (C)	DUOX2	mRNA	 determined	 by	 ISH	 using	 xenograft	 sections	










protein	 expression.	 Xenograft	 sections	 (5	 μM)	 were	 prepared	 and	 DUOX2	
































+ cetuximab Cetuximab 
	 262	
	














Control	 1.00±0.00	 1.00±0.00	 15.02±0.00	 0.58±0.00	
Cetuximab	 1.25±0.10	 1.06±0.05	 13.61±3.73	 0.88±0.26	








Ki67	 IHC	was	used	 to	determine	proliferating	 cells	within	 the	 xenografts	 (Figure	6.4.A,	
Figure	6.5)	(Table	6.2).	There	were	more	Ki67	positive	cells	in	xenografts	treated	with	a	



















Figure	 6.4.	 Effect	 of	 oxaliplatin	 and	 cetuximab	 treatment	 of	 DLD1	 xenografts	 on	
proliferation	 and	 apoptosis.	 Proliferation	 and	 apoptosis	 of	 DLD-1	 xenografts	 (n=3)	
treated	with	cetuximab,	oxaliplatin	alone	or	in	combination	were	assessed	using	Ki67	(A)	











































24	 hours.	 In	 support	 of	 the	 in	 vitro	 data,	 treatment	 of	 xenograft	 animals	 with	 a	
combination	of	cetuximab	and	oxaliplatin	showed	higher	tumour	proliferation	compared	
with	 oxaliplatin	 alone	 as	 highlighted	 by	 elevated	 Ki67	 staining	 and	 reduced	 cleaved	
caspase	3	staining.	DUOX2/DUOXA2	mRNA	expression	was	also	in	accordance	with	the	in	
vitro	 findings:	expression	was	 increased	by	oxaliplatin	treatment	alone	and	reduced	by	
combination	 with	 cetuximab,	 although	 statistical	 significance	 was	 only	 reached	 by	
DUOXA2.	The	same	pattern	was	observed	with	DUOX2	protein	levels133.	
In	response	to	oxaliplatin	therapy	alone,	the	increase	in	DUOX2	mRNA	and	protein	led	to	
subsequent	 elevation	 in	 ROS.	 Elevated	 ROS	 induced	 by	 oxaliplatin	 therapy	 resulted	 in	
activation	of	p38	and	subsequent	cell	death.	Cetuximab	has	inhibitory	effects	on	EGFR	as	
well	 as	ROS	production.	Combination	of	 cetuximab	with	oxaliplatin	 results	 in	 impaired	
activation	 of	 ROS-dependent	 cell	 death	 mechanisms	 induced	 by	 oxaliplatin	 via	
phosphorylation	of	p38.	ROS	is	known	to	modulate	response	to	chemotherapy	and	other	
studies	have	 shown	 involvement	of	different	NADPH	oxidases	 (NOX)	 in	producing	ROS	
following	chemotherapy497,506.		









need	 to	be	examined	 in	clinical	 samples	 from	patients	 receiving	oxaliplatin	alone	or	 in	
combination	with	cetuximab;	unfortunately,	these	specimens	were	not	available133.	The	
effects	 of	 combination	 treatment	 on	 ROS	 production	 demonstrated	 here	 needs	 to	 be	
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balanced	against	 the	contribution	made	by	EGFR	 inhibition	of	DNA	repair	and	 immune	
response,	which	would	potentially	favour	this	combination507,508.	This	could	explain	why	
the	 interaction	 of	 EGFR-inhibitory	 antibodies	 and	 chemotherapy	 is	 beneficial	 in	 some	
studies491,509.	It	is,	therefore,	critical	to	assess	the	effects	of	combining	drugs	for	therapy	
by	additional	approaches,	including	patient-derived	xenografts	and	analysis	of	circulating	
tumour	 cells.	 However,	 we	 have	 described	 an	 important	 mechanism	 of	 undesirable	
interaction	between	oxaliplatin	and	cetuximab	that	might	explain	why	a	subset	of	CRC	










can	 disrupt	 protein	 function	 and,	 therefore,	 lead	 to	 dysfunctional	 cell	 signalling	 and	
metabolism406.	 Previous	 studies	 of	 succination	 have	 shown	 it	 is	 increased	 in	 diabetic	
tissue343	and	in	HLRCC	where	one	copy	of	FH	is	not	mutated374.	
The	literature	has	previously	identified	an	increase	in	[fumarate]	in	CRC	tissue	compared	




succination	 in	 tumour	 tissue	 compared	 to	 the	 normal	 bowel.	 There	 is	 an	 additional	
increase	 in	 succination	 if	 the	 CRC	 sample	 is	 from	 a	 T2D	 compared	 to	 a	 non-diabetic	
patient.	 The	 2-SC	 staining	 was	 non-uniform	 across	 tumour	 tissue,	 underlining	 the	
metabolic	 heterogeneity	 of	 CRC.	 This	 is	 reinforced	 by	 evidence	 from	 in	 vitro	work	 in	




Upon	 further	 study,	 in	 Chapter	 3,	 it	 was	 noted	 that	 T2D	 patients	 with	 KRAS/BRAF	
mutations	 in	 cancers	 had	 more	 succination	 compared	 to	 T2D	 patients	 with	 WT	






would	 show	 some	 evidence	 of	 succination,	 but	 that	 there	 would	 be	 no	 significant	
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difference	 in	 2-SC	 staining	 intensity	 in	 polyps	 from	 diabetic	 and	 non-diabetic	 mice.	
Evidence	of	succination	was	found	in	DLD1	and	SW837	cell	lines,	however,	it	could	not	be	
linked	to	[glucose]	at	this	point.	I	would	hypothesise	that	CRC	cells	cultured	in	hypoxia	and	







it	was	unclear	 if	 FH	 staining	was	also	high	 in	mitochondria.	 Evidence	 from	 the	Human	
Protein	Atlas	suggests	that	FH	staining	is	intense	for	a	large	number	of	cancers	including	
CRC,	breast,	prostate,	liver	and	lung511.	It	is	possible	that	as	fumarate	levels	rise,	due	to	




role	 for	 cytoplasmic	 FH	 in	 tumourigenesis.	 Coupled	 with	 the	 fact	 that	 there	 are	 no	
indications	of	FH	mutation	in	human	CRC,	this	suggests	that	FH	remains	active	but	cannot	
control	 levels	 of	 fumarate.	 Studies	 involving	measurement	 of	 both	 [fumarate]	 and	 FH	
activity	in	CRC	tissue	would	bring	evidence	to	support	or	disprove	this	theory.			
In	Chapter	5	the	abundance	of	FH	in	vitro	did	not	correlate	with	levels	of	fumarate	in	CRC	
cells.	 It	 is	 necessary	 to	 quantify	 the	 level	 of	 FH	 in	 normal	 epithelial	 bowel	 cells	 to	
determine	 the	 difference	 between	 normal	 and	 cancer	 cells.	 However,	 FH	 activity	was	
lower	 where	 [fumarate]	 was	 increased,	 suggesting	 that	 FH	 activity	 is	 influenced	 by	
[fumarate]	or	vice	versa.	However,	[fumarate]	recorded	in	CRC	cells	in	this	study	was	not	





of	default	 in	FH325.	 It	would	be	 interesting	 to	see	 if	 there	are	differences	 in	FH	activity	
between	the	cytoplasm	and	the	mitochondria.		
In	Chapter	3	it	was	found	that	the	addition	of	FHcyt	reduced	the	available	glucose	found	in	







cells	 cultured	 in	 0mM	 glucose.	 This	 suggests	 that	 CRC	 cells	 are	 flexible	 with	 regards	
metabolism	pathways,	which	is,	of	course,	a	desirable	trait	for	cancer	cells.	Further	study	









The	additional	finding	that	overexpression	of	FH	 in	 intestinal	cells	 in	a	mouse	model	of	
CRC	leads	to	larger	polyps	was	also	novel.	It	is	yet	to	be	shown	if	more	intense	FH	staining	
in	CRC	leads	to	a	poorer	outcome	or	the	opposite.		












In	 a	 separate	 piece	 of	 work,	 in	 Chapter	 6,	 I	 was	 able	 to	 help	 identify	 that	 following	
treatment	 with	 oxaliplatin,	 DUOX2	 transcription	 is	 mediated	 by	 STAT1,	 whereas	
cetuximab	treatment	inhibits	STAT1	activation,	oxaliplatin-induced	DUOX2	upregulation,	
and	ROS	generation133.	This	mechanism	may	explain	why	CRC	patients	on	oxaliplatin	alone	





















e. If	T2D	 is	well	 controlled,	 is	2-SC	 lower	and	does	 this	 reduce	 the	risk	of	
CRC?		
2) What	is	the	role	of	FH	in	human	CRC?		


































- 2-SC	 IHC	 of	 normal	 and	 CRC/adenoma/dysplastic	 tissue,	 scored	 by	 a	 trained	
pathologist;	






































Section	 1.14).	 Ideally,	 the	 ‘perfect’	 model	 would	 have	 features	 similar	 to	 the	 human	
tumour	pathologies,	 such	 as	 polyps	which	progress	 to	 adenomas,	 cancers	 in	 the	 large	
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bowel	and	development	of	T2D	as	part	of	the	ageing	process	through	insulin	resistance	













































Additional	 further	 work	 questions	 based	 on	 the	 findings	 of	 the	 DUOX2	 chapter	 are	
outlined	below:		
1) What	is	the	optimum	level	of	DUOX2	and	production	of	hydrogen	peroxide	










3) Do	 all	 EGFR	 inhibitors	 reduce	 phosphorylation	 of	 STAT1?	 And,	 therefore,	
should	be	avoided	in	combination	with	oxaliplatin?		
Test	 if	 STAT1	 phosphorylation	 is	 inhibited	 in	 response	 to	 EGFR	 inhibitor	
therapy	in	CRC	cells.	Determine	if	DUOX2	mRNA	and	protein	levels	are	reduced	
after	EGFR	therapy	in	CRC	cells.	



















	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	162)	=	5.983	 0.0194	 *	
Non-diabetic	vs	T2D	 F	(1,	162)	=	75.33	 0.0059	 **	
Normal	vs	CRC	 F	(1,	1620)	=	6.074	 <0.0001	 ****	
	
Table	A.3.2.	Summary	of	Bonferroni	post	hoc	test	of	2-SC	score	for	matched	normal	and	










	Table	 A.3.3.	 Summary	 of	 two-way	 ANOVA	 of	 2-SC	 scores	 for	 matched	 normal	 and	
adenoma	tissue.	See	also	Figure	3.3.	
	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	56)	=	2.762	 0.1021	 ns	
ND	vs	T2D	 F	(1,	56)	=	2.125	 0.1505	 ns	























	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(2,	291)	=	7.454	 0.0008	 ***	
ND	vs	T2D	 F	(1,	201)	=	0.4049	 0.5253	 ns	
Normal	vs	CRC	 F	(2,	201)	=	78.08	 <0.0001	 ****	
	

















	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	74)	=	0.008782	 0.9256	 ns	
WT	vs	Mutant	 F	(1,	74)	=	2.445	 0.01222	 ns	









	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Interaction	 F	(1,	74)	=	0.008642	 0.9262	 ns	
WT	vs	Mutant	 F	(1,	74)	=	2.851	 0.0956	 ns	







	 F	(DFn,	DFd)	 p	value	 p	value	summary	






























		 F	(DFn,	DFd)	 p	value	 p	value	summary	
Total	 F	(7,	51)	=	3.332	 0.0053	 **	
	SB	 F	(7,	51)	=	3.432	 0.0044	 **	
LB	 F	(7,	51)	=	0.7037	 0.6687	 ns	
	
Table	 A.4.4.	 Summary	 of	 one-way	 ordinary	 ANOVA	 Bonferroni	 post	 hoc	 test	 of	 gut	
length.	See	also	Figure	4.5,	Table	A.4.6.	Only	significant	values	shown.	






































































		 F	(DFn,	DFd)	 p	value	 p	value	summary	




		 	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Site	 Interaction	 F	(9,	176)	=	0.9883	 0.4514	 ns	
Polyp	site	 F	(3,	176)	=	29.05	 <0.0001	 ****	
Genotype	 F	(3,	176)	=	5.397	 0.0014	 **	
Site	(%)	
Interaction	 F	(9,	176)	=	1.565	 0.1290	 ns	
Polyp	site	 F	(3,	176)	=	67.14	 <0.0001	 ****	



















		 	 F	(DFn,	DFd)	 p	value	 p	value	summary	
Size	 Interaction	 F	(9,	176)	=	1.135	 0.3402	 ns	
Polyp	size	 F	(3,	176)	=	2.883	 0.0373	 *	
Genotype	 F	(3,	176)	=	4.977	 0.0024	 **	
Size	(%)	 Interaction	 F	(9,	176)	=	2.169	 0.0263	 *	
Polyp	size	 F	(3,	176)	=	6.98	 0.0002	 ***	
Genotype	 F	(3,	176)	=	0.4521	 0.7161	 Ns	
SB1	 Interaction	 F	(9,	176)	=	2.089	 0.0328	 *	
Polyp	site	 F	(3,	176)	=	1.196	 0.3128	 ns	
Genotype	 F	(3,	176)	=	4.252	 0.0063	 **	
SB2	 Interaction	 F	(9,	176)	=	0.9839	 0.4550	 ns	
Polyp	site	 F	(3,	176)	=	1.38	 0.2506	 ns	
Genotype	 F	(3,	176)	=	2.783	 0.0424	 *	
SB3	 Interaction	 F	(9,	176)	=	1.15	 0.3303	 ns	
Polyp	size	 F	(3,	176)	=	3.899	 0.0099	 **	
Genotype	 F	(3,	176)	=	1.529	 0.2086	 ns	
LB	 Interaction	 F	(9,	176)	=	0.9324	 0.4984	 ns	
Polyp	size	 F	(3,	176)	=	3.829	 0.0109	 *	




































Cell	line	 F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	(Figure	5.1.A)	 F	(2,6)	=	26.49	 0.0011	 **	
HT55	(Figure	5.1.B)	 F	(2,6)	=	121.3	 <0.0001	 ****	

























Cell	line	 F	(DFn,	DFd)	 p	value	 p	 value	
summary	DLD1	(Figure	5.2.A)	 F	(2,6)	=	128.9	 <0.0001	 ****	





Table	A.5.4.	 Summary	of	Bonferroni	post	hoc	 test	 values	 for	doubling	 time.	 See	 also	
Figure	5.2.	
		 Conditions	 p	value	 p	 value	

























Interaction	 F	(2,	24)	=	37.86	 <0.0001	 ****	
Glucose	 F	(2,	24)	=	39.95	 <0.0001	 ****	




Interaction	 F	(2,	24)	=	9.151	 0.0011	 **	
Glucose	 F	(2,	24)	=	9.467	 0.0009	 ***	




Interaction	 F	(1,	8)	=	0.6403	 0.4467	 ns	
Cell	line	 F	(1,	8)	=	0.3504	 0.5702	 ns	






































Interaction	 F	(2,	12)	=	14.56	 0.0006	 ***	
Glucose	 F	(2,	12)	=	11.08	 0.0019	 **	




Interaction	 F	(2,	12)	=	2.660	 0.1106	 ns	
Glucose	 F	(2,	12)	=	37.15	 0.0001	 ****	




Interaction	 F	(1,	8)	=	43.66	 0.0002	 ***	
Cell	line	 F	(1,	8)	=	16.91	 0.0034	 **	




















































	 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	(Figure	5.7.A)	 Interaction	 F	(2,	12)	=	6.366	 0.0131	 *	
Glucose	 F	(2,	12)	=	14.06	 0.0007	 ***	
Oxygen	 F	(1,	12)	=	42.30	 <	0.0001	 ****	
SW837	(Figure	5.7.B)	Interaction	 F	(2,	12)	=	0.2118	 0.8121	 ns	
Glucose	 F	(2,	12)	=	5.672	 0.0185	 *	
Oxygen	 F	(1,	12)	=	6.084	 0.0297	 *	
MEFs	(Figure	5.7.C)	 Interaction	 F	(1,	8)	=	1.968	 0.1983	 ns	
Cell	line	 F	(1,	8)	=	15.34	 0.0044	 **	
Oxygen	 F	(1,	8)	=	1.239	 0.2980	 ns	
	
Table	 A.5.10.	 Summary	 of	 Bonferroni	 post	 hoc	 test	 values	 for	 fumarate	 hydratase	
activity.	Only	significant	values	shown.	See	also	Figure	5.7.		

























Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	 value	
summary	
DLD1	 FH	 foci	 per	 cell	
(Figure	5.9.A)	
Interaction	 F	(2,	12)	=	3.248	 0.0746	 ns	
Glucose	 F	(2,	12)	=	123.1	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	8.643	 0.0124	 *	
DLD1	 FH	 area	 per	 cell	
(Figure	5.9.B)	
Interaction	 F	(2,	12)	=	0.4272	 0.6619	 ns	
Glucose	 F	(2,	12)	=	144.7	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	0.005771	 0.9407	 ns	
SW837	FH	foci	per	cell		
(Figure	5.9.C)	
Interaction	 F	(2,	12)	=	4.164	 0.0423	 *	
Glucose	 F	(2,	12)	=	34.76	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	2.649	 0.1296	 ns	
SW837	FH	area	per	cell		
(Figure	5.9.D)	
Interaction	 F	(2,	12)	=	11	 0.0019	 **	
Glucose	 F	(2,	12)	=	47.57	 <0.0001	 ****	










DLD1	 FH	 foci	 per	 cell		
(Figure	5.9.A)	











DLD1	 FH	 area	 per	 cell		
(Figure	5.9.B)	


































Glucose	 Oxygen		 Glucose	*	Oxygen	 R	 Squared	
value	
BAX	 0.01370		 0.19994	 0.11366		 0.608292	
CA9	 0.01723	 0.00958		 0.01723		 0.468597	
PDK1	 0.01900	 0.00864	 0.66805	 0.503016	
LDHA	 0.02906	 0.00836	 0.08518	 0.560577	
HK2	 0.05156	 0.00221	 0.35933	 0.487454	
HIF12a	 0.07798	 0.03318	 0.13318	 0.404661	
VEGF	 0.08164	 0.11080	 0.57847	 0.3938	
GLUT1	 0.14398	 0.00125	 0.35915	 0.489338	
VHL	 0.19989	 0.08781		 0.19838		 0.708561	
GAPDH	 0.22010	 0.22010	 0.13628		 0.741091	
GPX1	 0.22787	 0.21652	 0.22787	 0.70272	
HIF1b	 0.23631	 0.22897	 0.23631	 0.713115	
LONP1	 0.33639	 0.18453		 0.27880		 0.535988	
HIF-1α	 0.46743	 0.06651	 0.58087	 0.659095	
FH	 0.50686	 0.03717		 0.50686		 0.817944	
COX4I2	 0.55882	 0.02499	 0.55882	 0.494927	
GLUT4	 0.73180	 0.05227		 0.45613		 0.636521	
SOD2	 0.73899	 0.73899	 0.74647	 0.552914	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 5.63E-06	 5.55E-06	 1.03E-05	 4.32E-06	 3.84E-06	 6.66E-06	
GLUT4	 7.14E-09	 3.51E-08	 4.08E-08	 1.56E-08	 5.91E-05	 2.22E-08	
GAPDH	 5.43E-04	 1.22E-03	 1.19E-03	 3.69E-04	 8.50E-04	 8.13E-04	
LDHA	 1.67E-05	 1.00E-04	 7.98E-05	 9.30E-06	 7.64E-06	 4.73E-05	
HK2	 2.89E-07	 1.82E-06	 1.17E-06	 2.19E-07	 1.07E-06	 7.07E-07	
FH	 1.14E-06	 3.20E-06	 3.21E-06	 5.77E-07	 1.10E-06	 1.99E-06	
PDK1	 4.03E-07	 2.21E-06	 7.67E-07	 2.51E-07	 1.72E-06	 5.08E-07	
LONP1	 9.60E-06	 2.07E-05	 2.20E-05	 4.14E-06	 2.14E-05	 1.20E-05	
SOD2	 1.46E-06	 1.10E-05	 4.78E-06	 7.87E-07	 6.84E-06	 4.04E-06	
COX4I2	 2.03E-09	 5.34E-09	 9.33E-10	 4.80E-09	 2.11E-08	 5.60E-09	
HIF-1Α	 9.49E-07	 4.92E-06	 2.77E-06	 6.52E-07	 3.25E-06	 1.76E-06	
HIF1B	 6.90E-07	 5.68E-06	 2.62E-06	 3.84E-07	 2.67E-05	 1.69E-06	
HIF-2Α	 4.30E-07	 1.78E-06	 1.19E-06	 3.31E-07	 1.84E-06	 1.09E-06	
VHL	 1.52E-06	 3.89E-06	 3.35E-06	 5.32E-07	 1.89E-06	 1.96E-06	
CA9	 4.42E-08	 1.25E-07	 6.15E-08	 1.92E-08	 1.60E-07	 3.72E-08	
VEGF	 7.50E-07	 4.56E-06	 3.22E-06	 8.52E-07	 1.06E-05	 3.78E-06	
BAX	 3.27E-06	 1.54E-05	 1.08E-05	 2.78E-06	 3.49E-07	 6.49E-06	
CASP9	 1.81E-07	 1.21E-04	 5.88E-07	 1.05E-07	 8.50E-04	 4.05E-07	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 8.02E-06	 7.74E-06	 1.23E-05	 3.08E-05	 2.05E-05	 4.14E-05	
GLUT4	 6.38E-09	 3.78E-08	 2.70E-08	 1.15E-08	 8.26E-09	 5.83E-09	
GAPDH	 3.54E-04	 5.06E-04	 5.22E-04	 1.10E-03	 1.51E-03	 1.30E-03	
LDHA	 1.25E-05	 2.16E-05	 2.25E-05	 1.24E-04	 1.96E-04	 1.97E-04	
HK2	 4.13E-07	 1.92E-06	 1.51E-06	 2.08E-06	 2.14E-06	 2.23E-06	
PDK1	 5.80E-07	 1.74E-06	 7.34E-07	 2.70E-06	 4.24E-06	 2.23E-06	
FH	 5.17E-07	 8.60E-07	 1.17E-06	 8.74E-07	 5.74E-07	 7.57E-07	
LONP1	 1.24E-05	 1.11E-05	 2.04E-05	 1.36E-05	 1.56E-05	 2.40E-05	
SOD2	 1.81E-06	 7.39E-06	 3.30E-06	 1.62E-06	 2.99E-06	 1.74E-06	
COX4I2	 1.15E-09	 1.43E-09	 1.74E-09	 1.66E-09	 4.57E-09	 1.42E-09	
HIF-1Α	 1.37E-06	 1.71E-06	 2.57E-06	 1.60E-06	 1.07E-06	 2.00E-06	
HIF1B	 1.30E-06	 3.59E-06	 2.89E-06	 1.04E-06	 2.98E-06	 2.04E-06	
HIF-2Α	 1.08E-06	 1.85E-06	 1.22E-06	 1.52E-06	 2.63E-06	 2.62E-06	
VHL	 1.15E-06	 2.97E-06	 2.92E-06	 2.49E-06	 9.86E-07	 1.81E-06	
CA9	 1.64E-08	 2.42E-08	 9.81E-09	 4.62E-06	 1.23E-05	 4.92E-06	
VEGF	 1.62E-06	 6.15E-06	 8.45E-06	 6.53E-06	 1.75E-05	 2.38E-05	
BAX	 3.54E-06	 6.96E-06	 4.09E-06	 5.02E-06	 6.83E-06	 4.25E-06	
CASP9	 1.62E-07	 3.05E-05	 3.47E-07	 2.60E-07	 4.46E-05	 4.01E-07	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 6.55E-05	 5.27E-05	 1.42E-04	 9.03E-05	 4.43E-05	 9.11E-05	
GLUT4	 1.02E-08	 9.51E-09	 1.71E-09	 3.20E-09	 5.21E-09	 6.54E-09	
GAPDH	 1.50E-03	 1.62E-03	 1.82E-03	 1.05E-03	 1.13E-03	 1.06E-03	
GPX1	 2.32E-05	 3.09E-07	 1.33E-05	 1.49E-05	 3.33E-07	 1.42E-05	
LDHA	 1.61E-04	 2.23E-04	 2.21E-04	 9.58E-05	 1.24E-04	 2.09E-04	
PDK1	 2.87E-06	 4.95E-06	 3.45E-06	 2.08E-06	 0	 2.21E-06	
HK2	 1.64E-06	 4.97E-06	 4.59E-06	 6.64E-06	 1.28E-05	 9.25E-06	
FH	 6.56E-07	 6.22E-07	 5.53E-07	 5.60E-07	 3.20E-07	 6.29E-07	
LONP1	 8.73E-06	 5.03E-06	 2.08E-05	 1.55E-05	 4.55E-06	 1.15E-05	
SOD2	 1.81E-06	 6.62E-06	 1.50E-06	 1.84E-06	 1.37E-06	 3.28E-06	
COX4I2	 1.41E-08	 8.94E-09	 2.52E-09	 6.84E-10	 6.14E-10	 1.30E-09	
HIF-1Α	 2.18E-06	 1.74E-06	 2.25E-06	 2.52E-06	 3.81E-07	 2.13E-06	
HIF1B	 1.10E-06	 2.01E-06	 1.67E-06	 3.21E-06	 2.13E-06	 5.85E-06	
HIF-2Α	 9.70E-07	 9.92E-07	 1.63E-06	 5.01E-06	 3.31E-07	 1.92E-06	
VHL	 1.06E-06	 6.18E-07	 1.05E-06	 2.34E-06	 7.72E-07	 8.20E-07	
CA9	 1.94E-06	 2.80E-06	 3.41E-06	 1.20E-06	 2.23E-07	 1.17E-06	
VEGF	 6.16E-06	 1.55E-05	 4.22E-05	 2.23E-05	 1.73E-05	 4.50E-05	
CASP9	 2.05E-07	 3.72E-05	 3.68E-07	 3.08E-07	 1.61E-05	 4.12E-07	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 1.61E-01	 2.61E-01	 2.76E-01	 7.25E-01	 6.74E-01	 1.12E+00	
GLUT4	 2.09E-04	 2.83E-04	 4.75E-04	 9.98E-06	 2.46E-05	 4.33E-05	
GAPDH	 4.75E-01	 2.39E-02	 7.14E-01	 5.44E-01	 1.33E-01	 9.76E-01	
GPX1	 2.86E-01	 2.24E-01	 2.46E-01	 1.10E-01	 9.39E-02	 1.23E-01	
LDHA	 1.67E-01	 7.22E-02	 2.64E-01	 2.65E-01	 1.44E-01	 5.45E-01	
PDK1	 3.00E-03	 3.34E-03	 4.60E-03	 1.56E-02	 1.15E-02	 1.58E-02	
HK2	 7.04E-03	 9.15E-03	 1.28E-02	 2.66E-02	 1.46E-02	 3.69E-02	
FH	 3.14E-02	 3.30E-02	 4.89E-02	 2.07E-02	 1.28E-02	 1.85E-02	
LONP1	 4.54E-02	 2.68E-02	 3.13E-02	 2.76E-02	 2.78E-02	 2.31E-02	
SOD2	 4.05E-02	 3.25E-02	 3.74E-02	 2.13E-02	 1.93E-02	 1.84E-02	
COX4I2	 8.21E-06	 1.10E-05	 1.52E-06	 1.49E-05	 8.93E-06	 1.67E-05	
HIF-1Α	 1.07E-02	 1.40E-02	 3.36E-02	 7.77E-03	 5.86E-03	 1.02E-02	
HIF1B	 4.80E-03	 2.35E-03	 4.55E-03	 2.21E-03	 1.93E-03	 2.94E-03	
HIF-2Α	 6.25E-03	 7.91E-03	 6.24E-03	 1.79E-02	 2.35E-02	 1.99E-02	
VHL	 1.35E-02	 1.26E-02	 1.86E-02	 4.70E-03	 4.77E-03	 5.89E-03	
CA9	 4.97E-04	 4.19E-04	 4.64E-04	 7.86E-03	 4.99E-03	 5.18E-03	
VEGF	 1.38E-02	 7.20E-03	 1.96E-02	 3.65E-02	 4.28E-02	 7.53E-02	
CASP9	 7.92E-04	 5.38E-04	 9.44E-04	 5.70E-04	 5.81E-04	 1.08E-03	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 1.24E-01	 1.28E-01	 1.40E-01	 3.68E-01	 5.93E-01	 7.26E-01	
GLUT4	 2.69E-04	 3.71E-04	 2.73E-04	 1.21E-04	 1.58E-04	 1.97E-04	
GAPDH	 2.88E-01	 6.18E-02	 2.83E-01	 3.73E-01	 2.53E-01	 5.54E-01	
GPX1	 1.94E-01	 1.11E-01	 1.29E-01	 1.25E-01	 6.02E-02	 1.14E-01	
LDHA	 1.79E-01	 8.22E-02	 1.77E-01	 5.25E-01	 2.15E-01	 4.91E-01	
PDK1	 2.20E-03	 3.95E-03	 2.25E-03	 1.83E-02	 1.07E-02	 1.71E-02	
HK2	 6.28E-03	 3.60E-03	 8.86E-03	 9.65E-03	 1.94E-02	 2.82E-02	
FH	 2.94E-02	 2.98E-02	 3.35E-02	 2.32E-02	 1.35E-02	 2.03E-02	
LONP1	 2.39E-02	 1.95E-02	 1.52E-02	 2.95E-02	 1.53E-02	 2.07E-02	
SOD2	 2.72E-02	 2.82E-02	 2.51E-02	 2.75E-02	 1.88E-02	 1.84E-02	
COX4I2	 1.70E-05	 5.25E-06	 6.18E-06	 1.96E-05	 2.22E-05	 1.40E-05	
HIF-1Α	 1.48E-02	 1.11E-02	 1.70E-02	 8.99E-03	 5.78E-03	 9.06E-03	
HIF1B	 2.38E-03	 1.55E-03	 1.94E-03	 1.82E-03	 9.74E-04	 1.49E-03	
HIF-2Α	 4.90E-03	 7.54E-03	 3.67E-03	 1.56E-02	 1.61E-02	 1.20E-02	
VHL	 1.01E-02	 9.41E-03	 1.14E-02	 6.99E-03	 3.01E-03	 5.38E-03	
CA9	 1.47E-03	 1.45E-03	 8.79E-04	 2.69E-02	 2.79E-02	 1.85E-02	
VEGF	 4.85E-03	 5.76E-03	 5.00E-03	 2.39E-02	 2.71E-02	 2.43E-02	
CASP9	 5.13E-04	 5.20E-04	 4.18E-04	 5.34E-04	 4.18E-04	 5.46E-04	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 7.38E-02	 1.02E-01	 1.54E-01	 5.85E-01	 5.19E-01	 1.32E+00	
GLUT4	 1.23E-04	 3.34E-04	 3.63E-04	 1.42E-04	 1.59E-04	 4.27E-04	
GAPDH	 2.86E-01	 8.80E-02	 3.33E-01	 9.12E-01	 2.26E-01	 7.02E-01	
GPX1	 1.44E-01	 9.80E-02	 1.44E-01	 1.24E-01	 8.18E-02	 1.70E-01	
LDHA	 1.77E-01	 8.41E-02	 2.05E-01	 7.47E-01	 1.88E-01	 7.75E-01	
PDK1	 2.21E-03	 2.24E-03	 2.85E-03	 2.06E-02	 1.03E-02	 2.70E-02	
HK2	 3.32E-03	 3.00E-03	 5.29E-03	 1.71E-02	 8.35E-03	 3.50E-02	
FH	 2.64E-02	 2.80E-02	 4.20E-02	 2.45E-02	 1.55E-02	 4.42E-02	
LONP1	 2.34E-02	 1.67E-02	 2.18E-02	 4.19E-02	 2.48E-02	 3.73E-02	
SOD2	 2.92E-02	 2.94E-02	 3.16E-02	 3.12E-02	 1.80E-02	 3.00E-02	
COX4I2	 1.61E-05	 5.28E-06	 1.79E-05	 1.53E-05	 1.42E-05	 2.93E-05	
HIF-1Α	 1.25E-02	 1.23E-02	 1.86E-02	 9.57E-03	 4.48E-03	 1.47E-02	
HIF1B	 2.05E-03	 1.44E-03	 2.47E-03	 2.46E-03	 1.08E-03	 2.50E-03	
HIF-2Α	 3.89E-03	 4.88E-03	 4.94E-03	 2.08E-02	 1.81E-02	 2.18E-02	
VHL	 7.30E-03	 8.20E-03	 1.22E-02	 6.82E-03	 5.31E-03	 1.71E-02	
CA9	 4.88E-04	 5.51E-04	 6.49E-04	 2.11E-02	 1.61E-02	 3.85E-02	
VEGF	 6.42E-03	 5.28E-03	 7.90E-03	 4.92E-02	 2.57E-02	 3.80E-02	
CASP9	 4.76E-04	 5.71E-04	 7.24E-04	 7.62E-04	 5.41E-04	 1.11E-03	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 1.21E-01	 1.61E-01	 8.08E-02	 1.08E-01	 1.40E-01	 8.53E-02	
GLUT4	 7.23E-05	 7.37E-05	 5.99E-05	 5.78E-05	 1.35E-04	 3.24E-05	
GAPDH	 2.83E+00	 3.86E+00	 2.36E+00	 2.74E+00	 4.75E+00	 2.12E+00	
GPX1	 1.23E-01	 9.82E-04	 9.75E-02	 1.30E-01	 1.81E-03	 8.43E-02	
LDHA	 1.26E-01	 1.53E-01	 1.15E-01	 1.31E-01	 1.17E-01	 1.04E-01	
PDK1	 4.42E-03	 8.80E-04	 1.43E-03	 5.09E-03	 3.69E-03	 1.91E-03	
HK2	 1.69E-03	 1.89E-03	 1.50E-03	 2.20E-03	 2.77E-03	 1.32E-03	
FH	 8.85E-03	 1.43E-02	 7.82E-03	 7.83E-03	 1.69E-02	 7.04E-03	
LONP1	 1.07E-01	 1.75E-02	 4.74E-02	 1.11E-01	 7.03E-02	 5.53E-02	
SOD2	 5.13E-02	 8.01E-02	 7.44E-03	 4.92E-02	 7.08E-02	 4.54E-03	
COX4I2	 5.60E-06	 0.00E+00	 1.71E-07	 0.00E+00	 2.50E-05	 9.26E-07	
HIF-1Α	 1.41E-02	 1.33E-02	 9.93E-03	 1.37E-02	 1.09E-02	 1.06E-02	
HIF1B	 1.12E-02	 4.24E-03	 4.34E-03	 1.12E-02	 1.15E-02	 3.65E-03	
HIF-2Α	 2.37E-03	 3.54E-03	 1.24E-03	 6.17E-03	 5.51E-02	 2.43E-03	
VHL	 9.65E-03	 7.40E-03	 4.79E-03	 9.89E-03	 1.05E-02	 5.28E-03	
CA9	 6.07E-04	 1.46E-05	 2.28E-04	 1.34E-03	 1.98E-05	 3.33E-04	
VEGF	 3.44E-02	 5.11E-02	 8.71E-03	 2.63E-02	 1.53E-01	 5.72E-03	
CASP9	 1.06E-03	 7.40E-02	 9.43E-04	 9.50E-04	 8.59E-02	 7.74E-04	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 8.74E-02	 1.46E-01	 5.65E-02	 1.05E+00	 2.67E+00	 6.27E-01	
GLUT4	 5.50E-05	 1.06E-04	 6.56E-05	 9.50E-05	 9.56E-05	 6.28E-05	
GAPDH	 1.62E+00	 2.80E+00	 1.81E+00	 5.37E+00	 9.22E+00	 5.94E+00	
GPX1	 7.51E-02	 1.30E-03	 7.13E-02	 1.10E-01	 1.66E-03	 1.20E-01	
LDHA	 6.50E-02	 7.09E-02	 5.06E-02	 6.08E-01	 1.22E+00	 5.21E-01	
PDK1	 5.96E-03	 1.93E-03	 1.90E-03	 2.82E-02	 4.74E-06	 1.60E-02	
HK2	 1.94E-03	 1.72E-03	 1.37E-03	 1.48E-02	 1.51E-02	 9.14E-03	
FH	 5.54E-03	 6.58E-03	 4.48E-03	 4.16E-03	 9.59E-03	 5.02E-03	
LONP1	 7.34E-02	 3.05E-02	 3.29E-02	 1.29E-01	 2.51E-01	 8.90E-02	
SOD2	 4.66E-02	 5.19E-02	 3.69E-03	 3.28E-02	 5.73E-02	 5.14E-03	
COX4I2	 0.00E+00	 7.45E-06	 0.00E+00	 8.34E-06	 3.81E-05	 9.57E-07	
HIF-1Α	 1.15E-02	 5.33E-03	 1.11E-02	 1.38E-02	 2.41E-04	 8.42E-03	
HIF1B	 9.69E-03	 7.52E-03	 4.31E-03	 1.16E-02	 1.07E-02	 4.31E-03	
HIF-2Α	 5.58E-03	 2.83E-02	 8.26E-03	 1.02E-02	 4.06E-03	 1.24E-02	
VHL	 8.17E-03	 6.16E-03	 5.62E-03	 4.84E-03	 2.09E-03	 7.15E-03	
CA9	 2.13E-03	 3.91E-04	 7.64E-04	 9.44E-02	 2.88E-02	 5.02E-02	
VEGF	 3.09E-02	 5.77E-02	 7.80E-03	 1.52E-01	 1.96E-01	 6.08E-02	
CASP9	 4.89E-04	 4.88E-02	 1.05E-03	 7.96E-04	 1.34E-01	 1.16E-03	







	 n=1	 n=2	 n=3	 n=1	 n=2	 n=3	
GLUT1	 8.17E-01	 7.84E-01	 7.05E-01	 9.28E-01	 1.82E+00	 1.47E+00	
GLUT4	 2.77E-05	 9.45E-05	 3.91E-05	 5.83E-05	 3.27E-05	 5.07E-05	
GAPDH	 4.77E+00	 1.03E+01	 3.49E+00	 5.17E+00	 5.39E+00	 3.81E+00	
GPX1	 1.03E-01	 1.39E-03	 8.37E-02	 1.07E-01	 1.25E-03	 5.58E-02	
LDHA	 4.66E-01	 8.61E-01	 5.06E-01	 5.24E-01	 4.78E-01	 5.54E-01	
PDK1	 3.04E-02	 2.00E-02	 1.73E-02	 3.45E-02	 1.23E-02	 1.57E-02	
HK2	 1.25E-02	 2.55E-02	 1.19E-02	 2.95E-02	 4.87E-02	 5.72E-02	
FH	 2.80E-03	 6.81E-03	 4.06E-03	 4.16E-03	 2.49E-03	 3.59E-03	
LONP1	 6.76E-02	 3.23E-03	 7.12E-02	 9.17E-02	 1.51E-02	 2.45E-02	
SOD2	 3.36E-02	 4.22E-02	 8.23E-03	 2.46E-02	 6.07E-02	 1.29E-02	
COX4I2	 2.79E-06	 0.00E+00	 0.00E+00	 0.00E+00	 6.53E-06	 0.00E+00	
HIF-1Α	 9.14E-03	 2.08E-03	 1.46E-02	 1.17E-02	 6.40E-03	 1.32E-02	
HIF1B	 1.14E-02	 7.99E-03	 4.87E-03	 1.21E-02	 1.79E-02	 2.30E-02	
HIF-2Α	 2.82E-02	 1.24E-02	 1.57E-02	 2.62E-02	 1.44E-01	 9.28E-02	
VHL	 4.33E-03	 9.60E-04	 5.82E-03	 5.61E-03	 3.74E-03	 5.17E-03	
CA9	 3.30E-02	 4.29E-03	 4.08E-02	 2.39E-02	 5.85E-03	 1.16E-02	
VEGF	 2.29E-01	 2.55E-01	 8.48E-02	 1.59E-01	 8.79E-01	 3.23E-01	
CASP9	 3.16E-04	 1.97E-01	 7.12E-04	 7.13E-04	 5.71E-02	 1.28E-03	




































0.01,	 ***	 p	 <	 0.001	 (A.5.35,	 A.5.36,	 A.5.38,	 A.5.39,	 A.5.41,	 A.5.42).	 See	 also	 Figure	











































	 25mM		 5mM	 0mM	
GLUT1	 1.00±0.00	 1.34±0.07	 11.63±1.24	
GLUT4	 1.00±0.00	 0.88±0.12	 0.58±0.43	
GAPDH	 1.00±0.00	 0.50±0.08	 1.87±0.44	
GPX1	 1.00±0.00	 0.88±0.37	 0.62±0.26	
LDHA	 1.00±0.00	 0.42±0.17	 4.88±2.38	
PDX1	 1.00±0.00	 1.06±0.19	 4.62±0.40	
HK2	 1.00±0.00	 1.26±0.11	 4.11±0.85	
FH	 1.00±0.00	 0.36±0.05	 0.31±0.13	
LONP1	 1.00±0.00	 0.92±0.22	 0.70±0.23	
SOD2	 1.00±0.00	 0.87±0.19	 0.72±0.27	
COX4I2	 1.00±0.00	 0.90±0.49	 3.77±1.61	
HIF-1α	 1.00±0.00	 0.90±0.32	 1.15±0.59	
HIF-1ß	 1.00±0.00	 1.21±0.37	 0.86±0.37	
HIF-2α	 1.00±0.00	 1.53±0.49	 1.39±0.49	
VHL	 1.00±0.00	 0.80±0.04	 0.39±0.16	
CA9	 1.00±0.00	 0.24±0.07	 40.54±9.69	
VEGF	 1.00±0.00	 2.05±0.37	 8.23±2.80	
CASP9	 1.00±0.00	 0.58±0.19	 0.69±0.24	
BAX	 1.00±0.00	 0.64±0.22	 0.78±0.38	
	 0.2%	
	 25mM		 5mM	 0mM	
GLUT1	 0.88±0.21	 2.09±0.94	 0.74±0.06	
GLUT4	 0.49±0.03	 0.33±0.11	 2.51±1.00	
	 318	
GAPDH	 0.95±0.26	 2.16±0.88	 1.04±0.34	
GPX1	 0.95±0.36	 1.17±0.36	 1.24±0.16	
LDHA	 0.88±0.46	 5.96±2.93	 1.06±0.33	
PDX1	 1.02±0.30	 1.89±0.86	 0.67±0.40	
HK2	 0.84±0.24	 0.93±0.38	 1.61±0.70	
FH	 0.98±0.50	 0.64±0.02	 0.94±0.21	
LONP1	 1.30±0.53	 1.17±0.14	 0.67±0.12	
SOD2	 1.11±0.38	 0.68±0.22	 1.12±0.57	
COX4I2	 3.46±1.63	 1.57±0.82	 7.06±6.77	
HIF-1α	 0.97±0.03	 1.03±0.20	 0.81±0.30	
HIF-1ß	 1.09±0.36	 0.93±0.17	 1.63±0.95	
HIF-2α	 1.08±0.11	 1.43±0.42	 0.57±0.31	
VHL	 1.31±0.77	 0.47±0.08	 0.83±0.23	
CA9	 1.39±0.49	 336.438±168.23	 0.68±0.48	
VEGF	 1.46±0.44	 1.97±0.86	 0.82±0.27	
CASP9	 0.97±0.38	 1.08±0.25	 0.74±0.20	










Interaction	 F	(2,	12)	=	51.21	 <0.0001	 ****	
Glucose		 F	(2,	12)	=	39.01	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	42.74	 <0.0001	 ****	
GLUT4	 Interaction	 F	(2,	12)	=	5.005	 0.0263	 *	
Glucose		 F	(2,	12)	=	2.557	 0.1188	 ns	
Oxygen	 F	(1,	12)	=	0.6377	 0.4401	 ns	
GAPDH	 Interaction	 F	(2,	12)	=	4.211	 0.0412	 *	
Glucose	 F	(2,	12)	=	0.6519	 0.5386	 ns	
Oxygen	 F	(1,	12)	=	0.5052	 0.4908	 ns	
GPX1	 Interaction	 F	(2,	12)	=	0.6723	 0.5287	 ns	
Glucose	 F	(2,	12)	=	0.05382	 0.9478	 ns	
Oxygen	 F	(1,	12)	=	1.493	 0.2452	 ns	
LDHA	 Interaction	 F	(2,	12)	=	4.56	 0.0337	 *	
	 Glucose	 F	(2,	12)	=	1.258	 0.3191	 ns	
	 Oxygen	 F	(1,	12)	=	0.1783	 0.6803	 ns	
PDK1	
	
Interaction	 F	(2,	12)	=	6.524	 0.0121	 *	
Glucose	 F	(2,	12)	=	2.838	 0.0979	 ns	
Oxygen	 F	(1,	12)	=	3.187	 0.0995	 ns	
HK2				 Interaction	 F	(2,	12)	=	3.539	 0.0619	 ns	
Glucose	 F	(2,	12)	=	9.632	 0.0032	 **	
Oxygen	 F	(1,	12)	=	6.208	 0.0284	 *	
FH		
	
Interaction	 F	(2,	12)	=	0.9929	 0.3990	 ns	
Glucose	 F	(2,	12)	=	2.431	 0.1299	 ns	
Oxygen	 F	(1,	12)	=	2.423	 0.1455	 ns	




Oxygen	 F	(1,	12)	=	0.6522	 0.4350	 ns	
SOD2	 Interaction	 F	(2,	12)	=	0.4144	 0.6698	 ns	
Glucose	 F	(2,	12)	=	0.3713	 0.6975	 ns	
Oxygen	 F	(1,	12)	=	0.1727	 0.6851	 ns	
COX4I2	 Interaction	 F	(2,	12)	=	0.1032	 0.9027	 ns	
Glucose	 F	(2,	12)	=	1.101	 0.3638	 ns	
Oxygen	 F	(1,	12)	=	0.7913	 0.3912	 ns	
	 320	
HIF-1α	 Interaction	 F	(2,	12)	=	0.2554	 0.7787	 ns	
Glucose	 F	(2,	12)	=	0.002182	 0.9978	 ns	
Oxygen	 F	(1,	12)	=	0.09108	 0.7680	 ns	
HIF-1ß	 Interaction	 F	(2,	12)	=	0.6335	 0.5476	 ns	
Glucose	 F	(2,	12)	=	0.1072	 0.8992	 ns	
Oxygen	 F	(1,	12)	=	0.2586	 0.6203	 ns	
HIF-2α	 Interaction	 F	(2,	12)	=	0.9099	 0.4286	 ns	
Glucose	 F	(2,	12)	=	1.145	 0.3508	 ns	
Oxygen	 F	(1,	12)	=	0.9285	 0.3543	 ns	
VHL				 Interaction	 F	(2,	12)	=	0.7323	 0.5011	 ns	
Glucose	 F	(2,	12)	=	1.659	 0.2312	 ns	
Oxygen	 F	(1,	12)	=	0.2547	 0.6229	 ns	
CA9	 Interaction	 F	(2,	12)	=	4.504	 0.0347	 *	
Glucose	 F	(2,	12)	=	3.531	 0.0622	 ns	
Oxygen	 F	(1,	12)	=	3.101	 0.1037	 ns	




Oxygen	 F	(1,	12)	=	5.515	 0.0368	 *	
CASP9		
	
Interaction	 F	(2,	12)	=	0.7331	 0.5008	 ns	
Glucose	 F	(2,	12)	=	0.6441	 0.5424	 ns	
Oxygen	 F	(1,	12)	=	0.7848	 0.3931	 ns	
BAX	
	
Interaction	 F	(2,	12)	=	0.412	 0.6714	 ns	
Glucose	 F	(2,	12)	=	0.0667	 0.9358	 ns	

















































	 25mM		 5mM	 0mM	
GLUT1	 1.00±0.00	 1.28±0.22	 2.18±0.22	
GLUT4	 1.00±0.00	 1.35±0.43	 1.29±0.25	
GAPDH	 1.00±0.00	 0.93±0.06	 1.90±0.20	
GPX1	 1.00±0.00	 1.12±0.13	 2.00±0.17	
LDHA	 1.00±0.00	 0.95±0.45	 1.03±0.13	
PDX1	 1.00±0.00	 1.18±0.30	 1.49±0.59	
HK2	 1.00±0.00	 1.59±0.20	 2.53±0.27	
FH	 1.00±0.00	 0.99±0.10	 1.18±0.01	
LONP1	 1.00±0.00	 0.96±0.14	 1.66±0.15	
SOD2	 1.00±0.00	 0.89±0.05	 1.22±0.08	
COX4I2	 1.00±0.00	 0.80±0.23	 13.42±13.17	
HIF-1α	 1.00±0.00	 1.00±0.09	 1.27±0.04	
HIF-1ß	 1.00±0.00	 1.01±0.11	 1.99±0.21	
HIF-2α	 1.00±0.00	 1.18±0.23	 1.50±0.12	
VHL	 1.00±0.00	 1.15±0.13	 1.64±0.11	
CA9	 1.00±0.00	 2.33±0.50	 0.83±0.09	
VEGF	 1.00±0.00	 0.83±0.14	 2.00±0.33	
CASP9	 1.00±0.00	 0.85±0.13	 1.30±0.21	
BAX	 1.00±0.00	 0.92±0.10	 1.32±0.12	
	 0.2%	
	 25mM		 5mM	 0mM	
GLUT1	 7.19±1.07	 5.17±0.33	 7.91±0.98	
GLUT4	 0.93±0.23	 0.67±0.16	 0.09±0.01	
	 323	
GAPDH	 2.65±0.44	 1.49±0.15	 2.42±0.42	
GPX1	 0.96±0.11	 0.76±0.07	 0.86±0.06	
LDHA	 3.42±0.60	 2.64±0.17	 1.96±0.36	
PDX1	 7.81±1.59	 6.36±1.03	 5.91±0.59	
HK2	 4.85±1.12	 4.90±1.05	 6.61±0.92	
FH	 0.84±0.15	 0.62±0.13	 0.56±0.11	
LONP1	 1.66±0.09	 1.04±0.11	 1.30±0.19	
SOD2	 0.88±0.14	 0.72±0.11	 0.66±0.04	
COX4I2	 1.76±0.50	 2.07±1.07	 1.91±0.98	
HIF-1α	 0.64±0.14	 0.56±0.08	 0.55±0.04	
HIF-1ß	 0.99±0.13	 0.72±0.09	 1.21±0.08	
HIF-2α	 4.48±0.47	 3.25±0.45	 4.48±0.24	
VHL	 0.99±0.22	 0.59±0.19	 0.57±0.05	
CA9	 38.16±11.54	 29.60±12.00	 31.94±14.94	
VEGF	 5.78±0.94	 3.98±0.61	 7.78±1.12	
CASP9	 1.36±0.21	 0.87±0.13	 1.23±0.14	






	 ANOVA	table	 F	(DFn,	DFd)	 P	value	 P	value	summary	




Oxygen	 F	(1,	12)	=	108.8	 <0.0001	 ****	




Oxygen	 F	(1,	12)	=	11.58	 0.0052	 **	
GAPDH	 Interaction	 F	(2,	6)	=	1.892	 0.2306	 ns	
Glucose	 F	(2,	6)	=	4.275	 0.0701	 ns	
Oxygen	 F	(1,	6)	=	11.26	 0.0153	 *	
GPX1	 Interaction	 F	(2,	12)	=	14.2	 0.0007	 ***	
Glucose	 F	(2,	12)	=	13.19	 0.0009	 ***	
Oxygen	 F	(1,	12)	=	35.69	 <0.0001	 ****	
LDHA	 Interaction	 F	(2,	12)	=	3.086	 0.0829	 ns	
Glucose	 F	(2,	12)	=	2.859	 0.0965	 ns	
Oxygen	 F	(1,	12)	=	46.99	 <0.0001	 ****	
PDK1	 Interaction	 F	(2,	12)	=	1.107	 0.3620	 ns	
Glucose	 F	(2,	12)	=	0.4465	 0.6501	 ns	
Oxygen	 F	(1,	12)	=	66.68	 <0.0001	 ****	
HK2				 Interaction	 F	(2,	12)	=	0.1384	 0.8721	 ns	
Glucose	 F	(2,	12)	=	2.735	 0.1050	 ns	
Oxygen	 F	(1,	12)	=	37.97	 <0.0001	 ****	
FH		 Interaction	 F	(2,	12)	=	2.563	 0.1184	 ns	
Glucose	 F	(2,	12)	=	0.6748	 0.5276	 ns	
Oxygen	 F	(1,	12)	=	21.19	 0.0006	 ***	




Oxygen	 F	(1,	12)	=	1.524	 0.2406	 ns	
SOD2	 Interaction	 F	(2,	12)	=	4.156	 0.0425	 *	
Glucose	 F	(2,	12)	=	1.598	 0.2426	 ns	
Oxygen	 F	(1,	12)	=	17.44	 0.0013	 **	
COX4I2	 Interaction	 F	(2,	12)	=	0.8937	 0.4347	 ns	
Glucose	 F	(2,	12)	=	0.8916	 0.4355	 ns	
Oxygen	 F	(1,	12)	=	0.5119	 0.4880	 ns	
	 325	
HIF-1α	 Interaction	 F	(2,	12)	=	0.9084	 0.4292	 ns	
Glucose	 F	(2,	12)	=	0.4395	 0.6543	 ns	
Oxygen	 F	(1,	12)	=	19.79	 0.0008	 ***	
HIF-1ß	 Interaction	 F	(2,	12)	=	4.496	 0.0349	 *	
Glucose	 F	(2,	12)	=	19.24	 0.0002	 ***	
Oxygen	 F	(1,	12)	=	12.11	 0.0045	 **	
HIF-2α	 Interaction	 F	(2,	12)	=	2.802	 0.1003	 ns	
Glucose	 F	(2,	12)	=	3.384	 0.0683	 ns	
Oxygen	 F	(1,	12)	=	131.7	 <0.0001	 ****	
VHL				 Interaction	 F	(2,	12)	=	7.499	 0.0077	 **	
Glucose	 F	(2,	12)	=	1.446	 0.2738	 ns	
Oxygen	 F	(1,	12)	=	23.82	 0.0004	 ***	
CA9	 Interaction	 F	(2,	12)	=	0.1492	 0.8629	 ns	
Glucose	 F	(2,	12)	=	0.09377	 0.9112	 ns	
Oxygen	 F	(1,	12)	=	18.23	 0.0011	 **	




Oxygen	 F	(1,	12)	=	70.85	 <0.0001	 ****	
CASP9		 Interaction	 F	(2,	12)	=	1.077	 0.3712	 ns	
Glucose	 F	(2,	12)	=	3.851	 0.0511	 ns	
Oxygen	 F	(1,	12)	=	0.6507	 0.4356	 ns	
BAX	 Interaction	 F	(2,	12)	=	7.667	 0.0072	 **	
Glucose	 F	(2,	12)	=	1.923	 0.1885	 ns	






	 	 P	value	 Bonferroni	 post	
hoc	 test	 value	
summary	









































































































































































































	 25mM		 5mM	 0mM	
GLUT1	 1.00±0.00	 0.78±0.07	 6.78±1.11	
GLUT4	 1.00±0.00	 1.10±0.19	 0.77±0.27	
GAPDH	 1.00±0.00	 0.69±0.06	 1.94±0.36	
GPX1	 1.00±0.00	 0.89±0.22	 1.04±0.19	
LDHA	 1.00±0.00	 0.47±0.02	 4.58±0.57	
PDX1	 1.00±0.00	 1.62±0.28	 6.33±3.51	
HK2	 1.00±0.00	 0.99±0.08	 9.59±1.95	
FH	 1.00±0.00	 0.55±0.05	 0.44±0.06	
LONP1	 1.00±0.00	 1.04±0.35	 0.77±0.39	
SOD2	 1.00±0.00	 0.68±0.12	 0.76±0.18	
COX4I2	 1.00±0.00	 0±0	 0±0	
HIF-1α	 1.00±0.00	 0.78±0.21	 0.76±0.38	
HIF-1ß	 1.00±0.00	 1.21±0.28	 1.34±0.28	
HIF-2α	 1.00±0.00	 5.67±1.71	 9.56±2.93	
VHL	 1.00±0.00	 0.95±0.11	 0.60±0.32	
CA9	 1.00±0.00	 11.18±7.75	 175.47±68.92	
VEGF	 1.00±0.00	 0.97±0.08	 7.13±1.39	
CASP9	 1.00±0.00	 0.75±0.19	 1.24±0.73	
BAX	 1.00±0.00	 1.26±0.16	 0.12±0.012	
	 0.2%	
	 25mM		 5mM	 0mM	
GLUT1	 1.02±0.07	 9.82±5.29	 1.76±0.45	
GLUT4	 1.21±0.37	 0.81±0.11	 0.71±0.30	
	 330	
GAPDH	 1.05±0.10	 2.29±1.00	 0.85±0.17	
GPX1	 1.22±0.31	 1.21±0.29	 0.84±0.09	
LDHA	 0.88±0.06	 9.19±4.95	 0.85±0.16	
PDX1	 2.13±1.04	 2.88±2.77	 0±0	
HK2	 1.04±0.22	 5.20±2.61	 1.39±1.29	
FH	 1.07±0.09	 1.30±0.10	 0.64±0.15	
LONP1	 2.04±0.98	 3.83±2.28	 1.92±1.38	
SOD2	 0.85±0.13	 1.31±0.10	 1.46±0.06	
COX4I2	 0±0	 0±0	 0±0	
HIF-1α	 0.97±0.08	 0.54±0.25	 1.59±0.75	
HIF-1ß	 1.52±0.60	 1.09±0.18	 2.63±1.11	
HIF-2α	 5.98±4.82	 0.73±0.41	 6.19±3.03	
VHL	 1.16±0.13	 1.10±0.40	 1.85±1.02	
CA9	 1.09±0.32	 46.47±23.33	 1.01±0.36	
VEGF	 1.65±0.70	 3.80±2.20	 2.90±0.74	
CASP9	 1.03±0.11	 1.49±0.66	 0.84±0.48	






	 ANOVA	table	 F	(DFn,	DFd)	 P	value	 P	 value	
summary	




Oxygen	 F	(1,	12)	=	0.5536	 0.4712	 ns	




Oxygen	 F	(1,	12)	=	0.0591	 0.8120	 ns	
GAPDH	 Interaction	 F	(2,	12)	=	4.72	 0.0307	 *	
Glucose	 F	(2,	12)	=	0.6163	 0.5562	 ns	
Oxygen	 F	(1,	12)	=	0.2744	 0.6099	 ns	
GPX1	 Interaction	 F	(2,	12)	=	0.8283	 0.4603	 ns	
Glucose	 F	(2,	12)	=	0.322	 0.7308	 ns	
Oxygen	 F	(1,	12)	=	0.4368	 0.5211	 ns	
LDHA	 Interaction	 F	(2,	12)	=	4.938	 0.0272	 *	
Glucose	 F	(2,	12)	=	1.83	 0.2025	 ns	
Oxygen	 F	(1,	12)	=	0.9465	 0.3498	 ns	
PDK1	 Interaction	 F	(2,	11)	=	1.634	 0.2391	 ns	
Glucose	 F	(2,	11)	=	0.4935	 0.6234	 ns	
Oxygen	 F	(1,	11)	=	0.3724	 0.5541	 ns	
HK2				 Interaction	 F	(2,	12)	=	8.117	 0.0059	 **	
Glucose	 F	(2,	12)	=	6.073	 0.0151	 *	
Oxygen	 F	(1,	12)	=	0.712	 0.4153	 ns	
FH		 Interaction	 F	(2,	12)	=	8.491	 0.0050	 **	
Glucose	 F	(2,	12)	=	17.75	 0.0003	 ***	
Oxygen	 F	(1,	12)	=	22.92	 0.0004	 ***	




Oxygen	 F	(1,	12)	=	2.973	 0.1103	 ns	
SOD2	 Interaction	 F	(2,	12)	=	8.88	 0.0043	 **	
Glucose	 F	(2,	12)	=	1.426	 0.2782	 ns	





















HIF-1α	 Interaction	 F	(2,	12)	=	1.173	 0.3426	 ns	
Glucose	 F	(2,	12)	=	0.9881	 0.4006	 ns	
Oxygen	 F	(1,	12)	=	0.3913	 0.5434	 ns	
HIF-1ß	 Interaction	 F	(2,	12)	=	0.8477	 0.4525	 ns	
Glucose	 F	(2,	12)	=	1.397	 0.2848	 ns	
Oxygen	 F	(1,	12)	=	1.597	 0.2303	 ns	
HIF-2α	 Interaction	 F	(2,	12)	=	1.902	 0.1916	 ns	
Glucose	 F	(2,	12)	=	1.785	 0.2096	 ns	
Oxygen	 F	(1,	12)	=	0.2222	 0.6458	 ns	
VHL				 Interaction	 F	(2,	12)	=	0.9011	 0.4319	 ns	
Glucose	 F	(2,	12)	=	0.09492	 0.9101	 ns	
Oxygen	 F	(1,	12)	=	1.835	 0.2004	 ns	
CA9	 Interaction	 F	(2,	12)	=	7.069	 0.0094	 **	
Glucose	 F	(2,	12)	=	4.447	 0.0359	 *	
Oxygen	 F	(1,	12)	=	3.613	 0.0816	 ns	




Oxygen	 F	(1,	12)	=	0.0722	 0.7927	 ns	
CASP9		 Interaction	 F	(2,	12)	=	0.8151	 0.4657	 ns	
Glucose	 F	(2,	12)	=	0.02722	 0.9732	 ns	
Oxygen	 F	(1,	12)	=	0.1163	 0.7389	 ns	
BAX	 Interaction	 F	(2,	12)	=	0.05282	 0.9488	 ns	
Glucose	 F	(2,	12)	=	1.128	 0.3556	 ns	



































































Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	 mitochondrial	 foci	
per	cell	(Figure	5.9.A)	
Interaction	 F	(2,	12)	=	19.68	 0.0002	 ***	
Glucose	 F	(2,	12)	=	86.35	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	8.261	 0.0140	 *	
DLD1	 mitochondrial	 area	
per	cell	(Figure	5.9.B)	
Interaction	 F	(2,	12)	=	7.364	 0.0082	 **	
Glucose	 F	(2,	12)	=	61.52	 <0.0001	 ****	
Oxygen	 F	(1,	12)	=	4.458	 0.0564	 ns	
SW837	 mitochondrial	 foci	
per	cell	(Figure	5.9.C)	
Interaction	 F	(2,	12)	=	0.518	 0.6084	 ns	
Glucose	 F	(2,	12)	=	17.27	 0.0003	 ***	
Oxygen	 F	(1,	12)	=	0.00	 0.9646	 ns	
SW837	 mitochondrial	 area	
per	cell	(Figure	5.9.D)	
Interaction	 F	(2,	12)	=	3.333	 0.0706	 ns	
Glucose	 F	(2,	12)	=	28.49	 <0.0001	 ****	




















































Table	 A.5.34.	 Summary	 of	 two-way	 ANOVA	 statistics	 for	 percentage	 of	 total	 FH	 in	
mitochondria	and	cytoplasm	per	cell.	See	also	Figure	5.16.	
Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	 value	
summary	
DLD1	–	FH	in	mitochondria	 Interaction	 F	(2,	12)	=	1.028	 0.3873	 ns	
Glucose	 F	(2,	12)	=	18.67	 0.0002	 ***	
Oxygen	 F	(1,	12)	=	6.511	 0.0254	 *	
DLD1	–	FH	in	cytoplasm	 Interaction	 F	(2,	12)	=	1.03	 0.3865	 ns	
Glucose	 F	(2,	12)	=	18.67	 0.0002	 ***	
Oxygen	 F	(1,	12)	=	6.516	 0.0253	 *	
SW837	 –	 FH	 in	
mitochondria	
Interaction	 F	(2,	12)	=	1.712	 0.2218	 ns	
Glucose	 F	(2,	12)	=	2.816	 0.0993	 ns	
Oxygen	 F	(1,	12)	=	3.117	 0.1029	 ns	
SW837	–	FH	in	cytoplasm	 Interaction	 F	(2,	12)	=	1.713	 0.2215	 ns	
Glucose	 F	(2,	12)	=	2.802	 0.1003	 ns	























25mM	vs	0mM	 Spare	capacity	 0.0018	 **	







































Measurement		 ANOVA	table	F	(DFn,	DFd)	 p	value	 p	value	summary	
DLD1	(Figure	5.18b.A)	 Interaction	 F	(10,	34)	=	2.675	 0.0157	 *	
Glucose	 F	(5,	34)	=	2.775	 0.0331	 *	
Oxygen	 F	(2,	34)	=	30.07	 <0.0001	 ****	
DLD1	 +	 25mM	 (Figure	
5.18b.B)	
Interaction	 F	(10,	36)	=	4.416	 0.0004	 ***	
Glucose	 F	(5,	36)	=	7.318	 <0.0001	 ****	
Oxygen	 F	(2,	36)	=	11.5	 <0.0001	 ****	
SW837	(Figure	5.18b.C)	 Interaction	 F	(10,	34)	=	1.394	 0.2245	 ns	
Glucose	 F	(5,	34)	=	2.878	 0.0285	 *	
Oxygen	 F	(2,	34)	=	25.23	 <0.0001	 ****	
SW837	 +	 25mM	 (Figure	
5.18b.D)	
Interaction	 F	(10,	36)	=	13.29	 <0.0001	 ****	
Glucose	 F	(5,	36)	=	33.22	 <0.0001	 ****	
Oxygen	 F	(2,	36)	=	20.97	 <0.0001	 ****	
MEFs	(Figure	5.18b.E)	 Interaction	 F	(5,	24)	=	7.802	 0.0002	 ****	
Glucose	 F	(5,	24)	=	7.802	 0.0002	 ****	










25mM	vs	0mM	 ATP	production	 0.0331	 *	
Max	resp.	 0.0005	 ***	
Spare	capacity	 <0.0001	 ****	






25mM	vs	0mM		 Proton	leak	 0.0082	 **	
Maximal	resp.	 <0.0001	 ****	
Spare	capacity		 0.0017	 **	
5mM	vs	0mM	 Maximal	resp.	 0.0373	 *	
Spare	capacity	 0.0017	 **	
25mM	vs	5mM	 Maximal	resp.	 0.0440	 *	
SW837	 (Figure	
5.18b.C)	
25mM	vs	0mM	 ATP	production	 0.0164	 *	
Maximal	resp.	 0.0061	 **	
Spare	capacity	 <0.0001	 ****	





25mM	vs	0mM	 ATP	production	 0.0140	 *	
Max	resp.	 0.0005	 ***	
Spare	capacity	 <0.0001	 ****	
5mM	vs	0mM	 Max	resp.	 <0.0001	 ****	
Spare	capacity	 0.0005	 ***	





WT	vs	KO		 Basal	resp.		 <0.0001	 ****	
ATP	production	 <0.0001	 ****	
Proton	leak	 <0.0001	 ****	
Maximal	resp.		 <0.0001	 ****	
Spare	capacity	 <0.0001	 ****	
Non-mito	resp.		 <0.0001	 ****	
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